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ABSTRACT
The quest for finding new antipsychotic drugs for schizophrenia, using clozapine as the 
model, with fewer side effects as compared to typical antipsychotic drugs, has produced 
quite a few new drugs in recent years. But none o f these are completely free of 
extrapyramidal side effects (EPS), a condition that gets worse by prolonged use of 
antipsychotic drugs by some patients.
In recent years, it has been hypothesized that a lower affinity towards dopamine D2 
receptors and higher affinity for serotonin (especially at 5HT2c receptors) for the new 
drugs may cause their atypicality and lower EPS.
Y931 is a new potential atypical antipsychotic drug (Morimoto et al., 2000). It is also 
classed as a multi-affinity receptor target agent. It is suggested that Y931 gives very few 
(if any) extrapyramidal side effects (Morimoto et. el., 2002) in animal models at standard 
medical dosage. Y931 has a similar receptor profile to clozapine and olanzapine. But 
unlike these and some other antipsychotic drugs, Y931 has relatively high affinity for 
dopamine D2 receptors. Thus some aspect of the pharmacology of Y931 could be 
different to clozapine and olanzapine and it may be working to suppress potential EPS 
generated by D2 antagonism in some different way than these drugs.
Y931 has very high affinity for 5HT2c receptors. There are significant levels of 5HT2c 
receptor luRNA present in the terminal areas of the dopaminergic system, e.g., striatum 
and the nucleus accmnbens. In vivo electrophysiological studies showed that the 
serotonergic system exerts an inhibitory action on the basal activity of midbrain DA- 
containing neurons. Thus it could be that there could be a functional relationship between 
serotonin and dopamine containing neurons, which could be either inhibition or 
facilitation of dopamine release. Several researchers showed that antagonism of 5HT2c 
receptors can affect dopaminergic modulation (Bonhaus et al., 1997; Di Matteo et al., 
1999; Kennett et al., 1997; Hutson et al., 2000; Wood et al., 2001).
The aim of this study is to investigate the characteristics and mechanisms of 
phaiinacological activity of Y931 in relation to extrapyramidal side effects.
We used three different studies to analyse the compound Y931. Firstly, we studied the 
immediate early gene (EEG) induction profile of Y931 (lOmg/kg, i.p.) together with 
haloperidol (Img/kg, i.p.) and olanzapine (lOmg/kg, i.p.) after 45 minutes following 
acute treatment. The level of expression of c-fos mRNA and ziG68 mRNA was 
monitored in a number of brain areas related to motor control. We also monitored fra-2 
mRNA in most of these areas. Results suggest that Y931 and olanzapine induced 
relatively less zif 268 mRNA expression in some layers of cortex as compared to 
haloperidol and/ or vehicle controls. In contrast, Y931 did not change c-fos mRNA 
expression in the motor cortex. In dorsal caudate putamen, Y931 increased zif 268 and c- 
fos mRNA expression. A similar effect was observed with haloperidol and olanzapine. 
This may reflect the high affinity of these drugs for receptors. In contrast to the results 
obtained with zif 268 and c-fos mRNA expression, no drug induced changes were 
observed in the level of fra-2 mRNA expression.
Secondly, we carried out a behavioural study on the effect of serotonin receptor 
antagonists using a 5HT2b/2c receptor antagonist (SB200646, 10 mg/kg, i.p) and a 
selective 5HT2c receptor (SB 242084) on haloperidol induced catalepsy. Y931 has very 
high affinity for serotonin receptors and it had been suggested that 5HT2c receptor 
antagonism may attenuate haloperidol induced catalepsy (Curzon and Kennett 1990, 
Eberle-Wang et.al. 1996; Reavill et.al.l999). Thus the result would be able to clarify the 
possibility of whether Y931 might be using this mechanism to combat the EPS. For this, 
we treated animals with haloperidol alone and also pretreated different groups of animals 
with SB200646 or SB242084 (both at 10 mg/kg i.p.), 15 mins before haloperidol. Other 
groups of animals were treated with Y931 (lOmg/kg i.p.) and olanzapine (10 mg/kg i.p.). 
The animals were then tested for catalepsy after different time points (up to 1 SOmins), 
using a block test, a grid test and a bar test. We compared the results of combined 
treatment (5HT2c receptor antagonist + haloperidol) with Y931 and olanzapine treated 
animals. The result of this study was not conclusive but suggested that all drug
combinations may cause catalepsy-like effects in these tests, although in the case of 
Y931, there was difficulty in distinguishing catalepsy from sedation.
Thirdly, we studied the induction profile of some marker genes in the different regions of 
the basal ganglia, which may be involved in the process of EPS after acute treatment with 
antipsychotic drugs. After 45 mins drug treatment none of the marker gene mRNA 
expression levels were changed. The expression level of GAD67 mRNA was 
significantly reduced in the lateral globus pallidus after treatment with Y931 compared to 
controls and haloperidol after 180 mins treatment with drugs. For parvalbumin and grp75 
(after 180 mins drug treatment), both mRNAs were expressed significantly higher than in 
control animals in the subthalamic nucleus after treatment with all three drugs. None of 
the marker genes showed altered expression of their mRNAs in the substantia nigra pars 
reticulata or substantia pars compacta. Furthermore, changes in the gene expression did 
not correlate with the degree of catalepsy detected.
Pretreatment with 5HT2c receptor antagonists showed change in the effect of haloperidol 
in the globus pallidus. In the lateral globus pallidus, Y931 and olanzapine, but not 
haloperidol reduced GAD 67 mRNA expression level. However, pretreatment of 
haloperidol treated rats with the SHTac receptor antagonist SB 242084 resulted in the 
reduction in GAD67 mRNA expression similar to that of olanzapine and Y931.
There was no change in the lateral globus pallidus after pretreatment with serotonin 
antagonists on the effect of haloperidol in the expression level of parvalbumin mRNA. In 
the subthalamic nucleus, pretreatment with the 5HT2c+b receptor antagonist but not the 
5HT%c receptor antagonist, significantly lowered the effect of haloperidol upon 
parvalbumin mRNA levels. This result was also significantly lower than haloperidol.
In substantia nigra pars reticulata, the expression level of GAD67 mRNA and 
parvalbumin mRNA did not change.
Overall, the results suggest that Y931 tends to increase striato-pallidal activity and pallido- 
subthalamic activity. The contribution of 5HT2c receptor activity is not clear. The higher 
affinity of Y931 for serotonin receptors (5HT2c) did not seem to relate to the ability of Y931 
to alter the activity of regions of the basal ganglia. The results suggest that Y931 affects 
striatal activity in a way predicted to lead to EPS. However, some action elsewhere in the 
basal ganglia may suppress this potential, although 5HT2c receptors are imlikely to be 
involved.
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AN INVESTIGATION OF THE ANOMALOUS LOW INCIDENCE OF 
MOTOR SIDE EFFECTS OF THE NOVEL ANTIPSYCHOTIC DRUG
-Y 931 .
CHAPTER 1: General Introduction
16
1.1. Schizophrenia : Nature of the Disease
Schizophrenia is a highly complex heterogeneous psychotic disorder of the brain that 
affects normal thinking patterns, the perception of reality, and ability to express or feel 
emotions. Thus this disorder affects virtually all-higher domains of mental functions. 
This diversity of symptoms makes it difficult to explain this disorder in tenns of any 
single type of dysfunction of any area of brain.
One person in a hundred develops schizophrenia in their late teens or early twenties, 
although it sometimes starts in middle age or even later in life. The characteristic time- 
course o f the disease includes extensive illness followed by chronic disability. The 
degree of disability ranges from mildly diminished ability to cope with stress, to severe 
difficulties in initiating and organizing voluntary activity. Although equal numbers of 
males and females are affected, some data suggests, that males may have more severe 
manifestations of the disorder, including an earlier age of onset (by 2-4 years) with more 
marked neuropathological abnormalities, poor response to treatment, and less favourable 
outcome (Szymanski et al., 1995, Hafuer. et al., 1998).
The symptoms of schizophrenia are categorized and classified by the International 
Classification of Disease (ICD-10) and the Diagnostic and Statistical Manual of the 
American Psychiatric Association, 4‘^  edition (DSM-IV). The positive symptoms are 
those that reflect the mental process that is not present in normal individuals and include 
hallucinations and delusions, formal thought disorder, inappropriate affect, together with 
poor ability of social interactions because of reality distortion. Where as poverty of 
speech, loss of emotional responsiveness, reduction of motor function and social 
withdrawal are often referred to as negative symptoms as they represent deficits from 
normal function. Negative symptoms also include the loss of motivation, anhedonia and 
emotional vibrancy. Disturbances in cognitive functions such as attention, precise 
memory, organization of social life are also continually hampered. These can greatly
17
limit the patient’s ability to function normally; lowering the quality of personal and social 
life causing concomitant mood symptoms such as depression and anxiety.
The criteria for diagnosis of schizophrenia can only be made, if  the clinical features are 
present through out a period of one month and in addition, there would be marked 
impairment of social or occupational functioning and continuous signs of disturbed 
mental functions for at least six months.
Characteristic symptoms Affective symptoms
Reality distortion Depression
Delusions Low mood
Hallucinations Low self-esteem
Hopelessness
Suicidality
Disorganization Psychomotor Excitation
Formal thought disorder Irritability
Disorganized or bizarre behavior Pressure of speech
Motor agitation
Psychomotor Poverty
Flat affect
Poverty of speech
Decreased motivation
Decreased voluntaiy motor activity
Non-specific symptoms -  Anxiety
Table 1. The symptoms of schizophrenia.
Although there was little or no evidence of a distinct relationship between symptoms and 
pathophysiology, the heterogeneity of the symptoms prompted many scientists to subtype 
the disease. Thus:
18
1) Paranoid schizophrenia characterized by reality distortion symptoms with relatively 
good preservation of personality.
2) Hebephrenia, which usually presents in adolescence or early adult life and is 
characterized by silly behaviour, fatuous affect, formal thought disorder and 
fragmented delusions.
3) Catatonia, which is dominated by episodic disorders of voluntary motor activity.
4) Simple schizophrenia characterized by gradual deterioration in function over a period 
of more than a year, without florid symptoms.
1.1.1 Time Course of Schizophrenia
The clinical course of schizophrenia suggests that the disease unfolds in distinct phases. 
Initially, there is a developmental insult to the CNS that does not result in psychosis. 
Evidence from the records of the children who developed the disease in later life, showed 
that most of them failed to learn the use of language within the normal time scale. Most 
of them also will be further behind in their school work than their classmates. They are 
usually introverted as if  they are shy. Thus they find it difficult to adjust with other 
children or adults around them (Done et al., 1994). These kinds of observations 
demonstrate an early association with subtle cognitive, motor function and social 
impairments, which may proceed to schizophrenia in the future.
19
1.1,2.  Factors Influencing Induction of the disease.
Environmental factors such as, exposure to infectious agents, toxins and traumatic insults 
and stress during gestation and parturition (Dalman et ah, 2001; Thomas et a l, 2001) or 
childhood may play a role in the pathogenesis of schizophrenia.
Life events, especially during the growing up phase of teenage to adulthood, insult of 
harmful drugs or chemicals may cause specific CNS injuiy.
Family, twin and adoption studies have demonstrated that, the morbid risk of 
schizophrenia in relatives, correlate with the degree of shared genes. Regions of a number 
of chromosomes (Scordo et a l, 2000 and Jones et a l , 1994) have been implicated as sites 
of potential vulnerability (Lewis and Lieberman 2000; Pulver, 2000; Marcelis, et a l, 
1998, Brustowicz et a l, 2000, Readier, et al., 2000). Obstetric complications (Dalman et 
a l, 2001; Thomas et a l, 2001) and various indicators of delayed development such as 
parental drug misuse during pregnancy (Heyser et a l , 1994; Lipton et a l, 1999; 
Stanwood et a l, 2001), during infancy and childhood, may point to a developmental 
deficit in neuronal function. Whether or not these risk factors act on their own or in 
conjunction with genetic and environmental factors, remains to be fully established.
There is substantial evidence for a developmental etiology of schizophrenia (Johnstone et 
a l, 1976; van Horn and McManus, 1992; Lawrie and Abukmeil, 1998; Marcelis et a l, 
1998; Lewis et a l, 1997 & 2000; Jarskog et a l, 2000; Raedler et a l, 2000). Autopsy 
studies showed cellular abnoimalities in the prefi*ontal and cingulate cortices of 
schizophrenic patients; a reduction in the number of GABA-containing interneurons; a 
reduction in the amount of G ABA made by these neurons (but no loss in their number); a 
reduction in the dendritic processes o f pyramidal neurons and a reduction in the tenninai 
markers. In recent years, the development of brain imaging and positron emission 
tomography has allowed the brains of schizophrenic patients to be studied directly within 
a cellular and molecular context.
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Thus, the cause of schizophrenia is likely to consist of genes conferring vulnerability and 
environmental insults, which express in the developmental maturation of brain circuitry. 
But the difference between schizophrenia and some of the other genetic 
neurodevelopmental diseases are that, there are no immediate overt manifestations of the 
disease. Rather most individuals appear to function normally until they enter the greatest 
period of risk in late adolescence and early adulthood. Thus, schizophrenia seems to be a 
polygenic disorder, associated with genetic environmental and developmental 
vulnerability factors.
From the discussion above it could be concluded that the interaction of an inherited 
predisposition to the disease condition and early neurodevelopment changes results in 
defective connectivity between some of the brain regions, e.g., midbrain, nucleus 
accumbens, subthalamic nucleus, thalamus, temporolimbic and prefrontal cortex (Jones, 
1997). This defective neural circuitry is then cause abnormal function expressing the 
disease-state of the individual.
21
1.1,3. Treatment of Schizophrenia
Schizophrenia was first treated with neuroleptic agents after the discovery of 
chlorpromazine in 1952 (Delay and Deniker, 1952). A number of studies compared the 
effects of these first generation antipsychotic drugs with those of general sedatives such 
as barbiturates that were in use before. These studies had shown that these compounds 
have a specific antipsychotic action that is not possessed by general sedatives (Klein and 
Davis, 1969). They have a completely different action to which the fundamental 
symptoms o f schizophreniawhich are uniquely characteristic of the disorder, responded 
selectively, This dramatically improved the treatment o f schizoplirenic patients. These 
medications calmed down the agitated patients and greatly modified the positive 
symptoms of schizophrenia effectively.
These drugs (Clorpromazine and Phenothiazine) were developed, using motor side 
effects such as catalepsy as an end point in the laboratory animals, because such effect 
were believed to be closely related to the therapeutic mechanism of the components of 
the drugs. Similarly, clinicians commonly used movement disorders in the patients, as an 
indicator of antipsychotic effects (Glazer, 2000). Thus the defining criteria of 
neuroleptics was the induction of an extrapyramidal syndrome. The drug that was 
discovered around this time was from Rauwolfia serpentia [(locally known as shawrpa 
gondha) used as medication for insane peoples for its tranquilizing properties] first 
described and used by Sen and Bose 1931. This was possible after isolation of the 
physiologically active ingredients responsible for treatment of psychiatric disorders. The 
new drug was marketed as reserpine. The similarities between the effects of reserpine on 
mental patients and that of phenothiazine were evident to Deniker and Delay. This drug 
also caused motor side effects at therapeutic doses identical to that of chlorpromazine, 
despite a very different molecular structure. This gave an incentive to find other 
compounds that could be similarly useful. In 1959 haloperidol, a non-selective dopamine 
antagonist, was introduced to the market. This was the neuroleptic to be used from then 
on for hallucinations, paranoia, delusions, etc., as in schizophrenia (Janssen, 1967, 1970;
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Lewi P J et a l, 1970). All these antipsychotic drugs are dopamine D% receptor 
antagonists. The mechanism of action o f these neuroleptic drugs used in the treatment of 
schizophrenia was generally considered as the blockade or disruption o f cerebral 
dopaminergic mechanism, in ‘mesolimbic dopamine’ (Costall and Naylor, 1975; Millar et 
a l, 1974; Carlsson et.al, 1978). They possess clinical efficacy in the treatment of 
positive symptoms and their ability to inhibit amphetamine-induced stereotypy (Carver 
et. a l , 1975). And these drugs are categorised as typical antipsychotic drugs.
However, the limitations of these agents became clearer within a few years. Neuroleptic 
agents inhibit other dopamine systems and, of these, the antagonism of striatal dopamine 
mechanisms was considered to play an important role in the development of 
Parkinsonian-like syndromes (Homykiewicz, 1973). And this accused the major 
disadvantage of these neuroleptic dings such as the development of a variety of 
movement disorders termed extrapyramidal side effects (EPS). More than 80% patients 
treated with the first generation neuroleptics expected to develop significant EPS that will 
often lead to non- compliance with medication. Although there was a gradual decline in 
the number of hospitalised patients, it took a few years to realise the effect of the 
extrapyramidal syndrome on the patients. Most patients released from hospital were not 
considered ‘cured’, but were in some stage of remission. Thirty percent o f patients may 
had been considered to be completely recovered, 60% may have experienced varying 
degrees of recovery, while 10% of schizophrenic patients failed to respond to treatment. 
And relapse rate was high. The blockade of mesolimbic D] receptors was believed to 
relieve positive symptoms (Carlsson et.al, 1978) but the difficulty was, treatment with 
typical antipsychotic drugs generated EPS.
All these reasons encouraged researchers to find other compounds that could have greater 
efficacy on the negative symptoms of schizophrenia and to cause fewer or none of the 
unwanted extrapyramidal side effects. The research resulted in the discovery of 
clozapine, which was patented in 1960. Clozapine became the model for newer drugs 
with the characteristics: 1) great efficacy on the negative symptoms of schizophrenia with
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2) very few, if any at ail, extrapyramidal side effects (Van Praag, et. a l, 1976; 
Baldessarini and Frankenberg, 1991).
Although all the dings, wliich are used to treat psychosis, are now termed as 
‘antipsychotic drugs’, the earlier drugs are also called ‘typical’ antipsychotic drugs as 
these are also associated with extrapyramidal side effects. Drugs that are developed on 
the basis of clozapine as a model for their characteristics are termed as ‘atypical 
antipsychotic drugs’ with fewer and less pronounced occurrence of EPS.
Subsequent research on the properties of chlorpromazine and haloperidol suggested that 
these compounds’ antipsychotic actions depend on their capacity to block D% dopamine 
receptors. According to the ‘dopamine hypothesis’, schizophrenia is caused by excessive 
dopaminergic neurotransmission or high level of D2 -  like receptors in the brain. Thus the 
ability to block postsynaptic D2 receptors is the characteristic biochemical effect of all 
classical antipsychotics.
Thus it was proposed that neuroleptics like chlorpromazine and haloperidol block the 
post-synaptic Di receptors. Seeman et a l (1976) linked the efficacy of these drugs to 
their D2 receptor binding affinity. And in recent years (Kapur et.al.,2000b; Farde et.al,
1992), positron emission tomography (PET) confirmed the correlation between the D2 
receptor occupancy rate and the clinical efficacy and onset of EPS.
Few remedies have been found for these neuroleptic-induced movement disorders, which 
had prompted research to look for drugs with better efficacy.
Clozapine is the prototype atypical antipsychotic drug that produces no EPS or very few 
(Costall and Naylor, 1975) if  any at all and appears to be effective in reducing many 
symptoms of schizophrenia (Meltzer and McGurk, 1999; Lieberman et.al, 1994; Lee et. 
a l , 1994). These characteristics of clozapine led many authors to seriously question the 
inseparability of antipsychotic-Parkinsonian like effects (Costall and Naylor, 1975). Thus 
it was believed that in the core of atypicality is a reduced liability of EPS and less or
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devoid of other adverse effects of the drugs, such as -  sedation, autonomic movements, 
sexual arousal and other adverse effects. Therefore a clozapine like drug (an atypical 
antipsychotic) without its harmful haematological side effects will be most helpful to the 
patients with schizophrenia. Clozapine has high affinity for D2 dopamine receptors but.
Atypical ADP Typical ADP
1. Clozapine Amisulpride / Sulpiride
2. Olanzapine Ciorpromazine
3. Risperidone Reserpine
4. Perspirone Haloperidol
5. Sertindole Loxapine
6. Ziprasidone Thioridazine
7. Zotepine Proclorperazine
8. Tiospirone Perphenazine
9. Fluperlapine Mesoridazine
10. Tenilapine Triflurperidol
11. Quetiapine Thiothixene
Table 2, List of some of the most-widely prescribed antipsychotic drugs in the market.
not as high as the typical APD. It also has very high affinity for various type of 5- 
hydroxytryptamine (5-HT) receptors, most notably the 5 -HT2 receptors. In recent years 
more receptors for dopamine and serotonin receptor subtypes have been discovered e.g., 
D3, D4; 5 -HT2A, 5 -HT2B, 5-HT 2c , 5-HT6 , 5-HT?. This has made the receptor 
pharmacology of clozapine very complex. Other than serotonin, clozapine also has high 
affinity for adrenergic, muscarinic, and histaminergic receptors (Meltzer and McGurk, 
1999).
One view of the mode of action of atypical antipsychotic is that, these drugs interact with 
brain 5 -HT2A, or 5 -HT2B or 5 -HT2C serotonin receptors, wlule also occupying dopamine 
D2 receptors. One of the characteristics of these drugs is that they bind to 5 -HT2 with a 
higher affinity than to D2 receptors. It is thought that there is a definite ratio between 5- 
HT2A and D2 receptor affinity for their atypical anti psychotic properties (Meltzer et.al.
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1989,1991; Kapur e t  al. 1999, 2000a; Wadenberg et. al., 1997; Neal-Beliveau et.al.,
1993). These drugs are also referred as serotonin, dopamine inhibitors (SDI).
The quest for finding new drugs with similar pharmacology as for clozapine and new 
knowledge from the study of clozapine helped to produce a number of new generation 
antipsychotic drugs, such as: risperidone, olanzapine, quetiapine, ziperasidone, 
seritindole and so on in the recent years. Like clozapine, therapeutic doses of quetiapine 
cause very few or minimal EPS (Casey, 1996, 1997).
DRUGS Receptor affinity (Ki, nmol/L)
D1 D2 D3 D4 5-HT
lA
5-HT
2A
5-HT
2C
a -1 a-2 M-1 M-3 M-4 H i
Cloz 190 220 92 43 120 5.0 4.8 3.6 300 47 30 - 9.8
Olatiz 45 28 51 38 1600 2.6 1.2 11 1200 57 210 120 24
Y931 36 2.5
-4.5
1,9 20 230-
630
1.7-
9.62
9.62 1.5-
3.1
340 12 7.1 20 36-54
Halop 150 2.0 2.7 3.7 1200 59 5800 5.5 >1000 >1000 - - 3900
Table 3. Comparison of binding affinities of Y931 with Clozapine, Olanzapine and 
haloperidol for various receptors that may be involved in extrapyramidal side effects 
(EPS) [Meltzer et al., 1989; Arnt and Slearsfeldt., 1998; Hilger and Kasper., 2000]
It is believed that atypical antipsychotic drugs preferentially activate the dopaminergic 
systems of limbic structures but not the striatum (Cessa et.al., 2000; Jaskiw et. al., 2001; 
Chen et.al, 1991).
Y931 {8-fluoro-12-(4-methylpiperazin-1 -yl)-6H[ l]benzothieno[2,3b] [ 1,5]benzodiazepine 
maleate} is a new multi-affinity compound with a similar pharmacology to clozapine 
(Morimoto et al, 2002).. However, despite its higher affinity for D2 receptors than 
clozapine and other antipsychotic drugs, it appears to exhibits few EPS in preliminary 
studies (Morimoto et al, 2002).
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1.1.4. Extrapyramidal syndrome: A side effect of treatment with 
antipsychotic drugs
Since 1950s the patients diagnosed with schizophrenia, are treated with antipsychotic 
drugs, mostly haloperidol Although it reduces overall severity of the illness, using the 
drug for longer periods, (within the '‘optimal dosage") brings on the motor side effects, 
along with the other side effects. The motor side effects caused by neuroleptics are 
categorised as extrapyramidal side effects because they relate to the drug actions outside 
the pyramidal motor system (Schillevoort, et al. 2000) such as the striatum, globus 
pallidus and substantia nigra, which control voluntary movements. PET analysis of 
patients with acute EPS indicates that it is caused due to occupancy of at least 80% of D% 
receptors in the basal ganglia (Farde et.al, 1992). EPS normally occurs in acute and late 
onset (tardive) forms. Most of these symptoms undergo remission after the drug 
treatment stops.
In normal condition there is a balance between dopaminergic and cholinergic tone in the 
striatum. In schizophrenia, this balance is disturbed due to dopaminergic hyperactivity.
It is now generally accepted that the ability of the ‘typical’ or early generation anti 
psychotic drugs (APD) and also the newer ‘atypical’ antipsychotic drugs (to a lesser 
extent), to cause extrapyramidal side effects can be correlated with their high affinity to 
the Dz dopamine receptors in the striatum. Blockage of the Dz dopamine receptors by the 
typical antipsychotic drugs, increases the activity of the indirect (excitatory) striatal 
output pathway to the substantia nigra via the globus pallidus, and subthalamic nucleus 
and decreases the activity of the direct (inhibitory) pathway to the substantia nigra. These 
results in increased descending output from the substantia nigia, causing disturbances in 
the motor circuits, effecting Parkinson’s like side effects known as the extrapyramidal 
side effects. Knockout mice lacking Dz receptors, but not those lacking Di, Dg or D4 
receptors, exhibit catalepsy, the experimental counterpart of Parkinsonism. Thus 
antagonism of the D2 and D3 receptor (D% like receptors) but not the other dopamine 
receptors, is the most likely cause of neuroleptic-induced Parkinson like syndrome.
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Extrapyramidal side effects can take a variety of forms. There are four major categories 
ofEPS.
a) Parkinsonism
b) Tardive dyskinesia (TD)
c) Dystonia
d) akathisia
a) Parkinsonism consists of a parkinsonian syndrome that resembles true Parkinson 
disease. The symptoms include tremors in hand and anns, rigidity, spasticity or 
difficulty in initiating movements, and akathesia or restlessness, emotions are less 
expressive. Patients could experience this symptom within a very short time, within 
days or weeks after the treatment starts.
b) Tardive dyskinesia (TD) is a more severe disorder of movement of muscles. It affects 
face and neck irregular involuntary muscle movements, usually in the face around the 
mouth. But it could also be in the arms, legs and body. TD develops after prolonged 
exposure to the neuroleptics and can become irreversible. TD is the most severe side 
effect of the first generation neuroleptics and believed to be caused by super 
sensitivity response to chronic dopamine blockade. It is very common after repeated 
drug treatment and is not readily reversible after cessation of drug treatment. Because 
of this reason, TD has severely limited the use of classical neuroleptics.
c) Dystonia is a sudden and severe spastic movement of muscles of face and neck. 
Acute dystonia can occur during the second or third day of treatment.
d) Akathisia is a syndrome chaiecterised by a subjective sense of anxiety and 
restlessness. EPS-related akathesia is often mistaken for psychotic agitation.
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When ail the parameters are fully explored, it was found that each fonn of EPS has 
unique characteristics.
Y-931, 8-fluoro-12-(4“methylpiperzin-l-yl)-6H[l]benzothieno[2,3b][l,5]benzodiazepine 
maleate, is a very new multi-affinity compound, with similar receptor profile like 
clozapine, olanzapine and resperidone. Y931 also interacts with multiple neurotransmitter 
receptors such as dopaminergic, serotonergic, a-adrenergic, muscarinic and histaminergic 
receptors. Y931 is active in a dose-dependent manner in inhibition of apomorphine- 
avoidance responses. It has the property to ameliorate NMD A receptor hypofunction. It 
has potent protective action against the dizocilpine-induced neurotoxicity in the 
retrosplenial cortex and it has power to reverse dizocilpine-induced social deficits at the 
same doses at which it is neuroprotective (Morimoto et al, 2002).
The preliminary experiments seem to indicate that Y931 has the important property of an 
atypical antipsychotic drug with very few EPS, despite its higher affinity for D] receptors 
than clozapine and some other atypical antipsychotic drugs. Thus finding the exact site / 
sites of the physiological action that attenuate the effect causing EPS, could be of major 
significance for the understanding of Y931’s pharmacology, and for the development of 
antipsychotic drugs with improved efficacy.
The aim of this project is to try and uncover this aspect of the characteristics o f the Y-931 
compoimd.
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1.1.6. Brain regions involved in extra pyramidal syndrome:
Brain regions that are commonly implicated with schizophrenia are: 1) Temporal and 
parietal association cortices, 2 ) Prefrontal cortex, 3) Anterior cingulate cortex, 4) Basal 
ganglia, 5) Thalamus, and 6 ) Ventral mesencephalon (Lewis and Lieberman, 2000).
Motor activity is controlled by three major systems: cerebral cortex, basal ganglia and 
cerebellum. The basal ganglia are a group of subcortical nuclei of the vertebrate brain 
that are intimately involved in the control of movement. The organisation and 
connections of rat basal ganglia had been shown to be very similar to those in the human 
basal ganglia.
Drug-induced EPS thought to be mediated at the level of the basal ganglia. The diagram 
on page 31 and 46 illustrates the different brain structuies of the basal ganglia and how 
these relate to the other brain regions.
The grey matter that lies deep within the cerebral hemisphere forms the subcoitical nuclei 
or basal ganglia, which are the important structures involved in the control of extra- 
pyramidal movement. These include striatum (caudate/putamen and ventral striatum), 
globus pallidus (intemal-GPi, and extemal-Gpe), subthalamic nucleus (STN) and 
substantia nigra [a) pars compacta (SNc) and b) pai s reticulata (SNr). They are a complex 
and highly interconnected group of nuclei. In the rat GP is a single entity equivalent to 
the GPe in the primates and connected to the entopeduncular nucleus (EP) (Parent and 
Hazrati, 1995; Smith et a l, 1998; Heimer et a l, 1995).
The caudate/putamen have identical cell types as they are both developed from the same 
telencephalic structure and are anteriorly joined together. These two structures together 
are known as neostriatum or striatum. They are the input nuclei (or gateway) for the basal 
ganglia and receive fibers from all functional parts of cerebral cortex and intralaminar
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ganglia and receive fibers from all functional parts of cerebral cortex and intralaminar 
nuclei of the thalamus. The cortico-striatal projection originates from neurons located in 
both supra-granular and infra-granular cortical layers in each cortical
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Fig.l. Functional anatomy of brain regions involved in the dopamine and serotonin 
pathways (Adopted from Target Schizophrenia’ -  The association of the British 
Pharmaceutical Industry Edited by B. Kirkness, 1997).
region. The cortico-striatal projection originates from neurons located in both supra- 
granular and infra-granular cortical layers in each cortical region. The decrease in the 
number of neurons in the striatum compared to the cortex suggests a high degree of 
convergence in the organisation of the cortico-striatal projection. A feature of the cortico-
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striatal system is the marked heterogeneity of its tenninai fields in the form of clusters of 
various sizes - the striosomes (or patches) and the extrastriosomal matrix. Striosomes 
receive afferents mostly from prefrontal and limbic cortices. The neurons projecting from 
the cortex are glutamatergic.
Striatum
The striatum is composed of both projection neurons (Golgi type I cells) and local 
interneurons (Golgi type II cells). Projection neurons have a medium-sized cell body with
4-5 dendrites, which contain numerous spines (hence medium spiny neurons) and they 
are GABAergic and also coexpress substance P, enkephalin, dynorphin and neurotensin. 
The medimn spiny neuron is the main integrating element of the striatum, thus they are 
the major tai get of both local and extrinsic afferents. The medium spiny neuron integrates 
information that comes from a wide variety of afferents and conveys the result o f this 
complex neuronal computation outside the striatum. Intemeurons on the other hand have 
none or rarely any spines on their dendrites. A small number of the interneurons are 
GABAergic and also contain parvalbumin. The majority of the interneurons contain 
somatostatin, neiuopeptide Y, (NADPH)-diaphorase, which is involved in the synthesis 
of nitric oxide (NO) and use acetylecholine as neurotransmitter. But they do not express 
GAD mRNA.
The striatum receives an innervation from the substantia nigra pars compacta and dorsal 
raphe nucleus. They are dopaminergic and serotonergic respectively. Efferent fibers from 
the striatum terminate mainly in the substantia nigra reticulata and in the lateral and the 
medial segments of the globus pallidus and entopeduncular nucleus (GPi) and also the 
subthalamic nucleus in primates and human.
The efferents from the ventral striatum (accumben core and shell) project to the ventral 
and ventromedial pallidum, entopeduncular nucleus and lateral part of the ventral 
tegmental area. This suggests that the ventral striatum can affect the activities of the 
dorsal striatum via the mesencephalic dopamine system.
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Globus pallidus
The globus pallidus or pallidum is derived from diencephalon. In the human, it is divided 
into internal (GPi) and external segments (GPe). There are at least two types of neurons 
in the globus pallidus, spiny and aspiny, displaying different dendritic fields. The 
dorsolateral part of globus pallidus is richer with cytochrome oxidase, and ventromedial 
part is rich with acetyl cholin-esterase.
The globus pallidus-intemal (GPi) and substantia nigra reticulata constitute the major 
output nuclei of the basal ganglia. Both structuies project to specific thalamic relay 
nuclei, the ventral anterior and ventral lateral nuclei, which in turn project back to the 
cerebral cortex.
One of the most prominent efferent projections from globus pallidus is to the 
subthalamic nucleus. The other important targets of the GPi efferent pathways include 
projections to the mediodorsal and reticular thalamic nucleus and the lateral hebaniila at 
diencephalic levels, as well as the pedunculopontine tegmental nucleus at mesopontine 
brainstem levels and substantia nigra (both SNRand SNCD). In rat, the important targets 
of the globus pallidus projections include superior colliculus. In rat individual pallidal 
neurons may send collateral branches to the striatum, and the substantia nigra pars 
reticulata (Staines and Fibiger, 1984).
The ascending projections of pedunculopontine tegmental nucleus provide a massive 
innervation to the substantia nigra compacta, subthalamic nucleus and pallidum.
Thus the major outflow of the basal ganglia in rat is directed through the entopeduncular 
nucleus (GPi) and substantia nigra reticulata neurons, which send many collateral axon 
branches to the thalamus and brain stem (Parent et al., 1983; Bentivoglio et al., 1979). 
These two structures share many histological characteristics. In the rat, the 
entopeduncular nucleus and nigral projections overlap (Smith et al., 1998).
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Substantia nigra
The substantia nigra lies in the midbrain and has two zones -  a) ventral pale zone, the 
pars reticulata, b) dorsal darkly pigmented zone, the pars compacta. The lateral margin of 
the rostral half o f the SNR exclusively contains the nigro-tectal cells and is called 
substantia nigra pars lateralis (SNL). The internal segment of globus pallidus and 
substantia nigra pais reticulata have very similar cell types, connectivity and function, 
they are sometimes regarded as a single structuie. Various projection neurons in the 
substantia nigra pars reticulata receive input directly from the striatum (Williams and 
Faull, 1985) and from entopeduncular nucleus or GPi (Smith et a l, 1998; Heimer et a l, 
1995).
The substantia nigra gives rise to the descending projections to the pedunculopontine 
tegmental nucleus, as well as to the superior colliculus.
Subthalamic nucleus
The subthalamic nucleus (STN) lies below the thalamus at its junction to midbrain, dorsal 
to the cerebral peduncle between substantia nigra and entopeduncular nucleus (EP) in the 
rat. Neurons in the subthalamic nucleus are immunopositive to glutamate rather than G ABA 
ergic, as previously thought (Robledo and Féger, 1990). This nucleus exerts an inhibitory 
effect on the output nucleus of basal ganglia, and absence of this control due to any lesion 
was thought to be the cause of ballism, characterised by involuntary movements (Smith et 
a l, 1998).
Bevan et a l, (1994) demonstrated that neurons of the striatum (direct pathway) innervate 
common regions of tiie EP/Gpi or SNR. Terminals from striatum and STN (indirect
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pathway) form convergent synaptic contacts with individual dendiites and perikarya in both 
EP and SNR. Some of these neurons project to the ventral medial nucleus of the thalamus 
(Bevan et al., 1994). The same authors had shown that individual output neurons in the EP 
or SNrRthat receive synaptic input from striatum also receive synaptic input from terminals 
derived from tlie STN and GP. Thus groups o f neurons in the Gpi / EP, STN and SN are 
likely to be reciprocally connected, (van der Kooy et a l, 1980). The intralaminar nuclei of 
the thalamus, the dorsal raphe, the mesopontine tegmentum and the dopaminergic cells in 
the SNCD also innervate the STN (Bevan et a l, 1995).
Although the striatum is commonly seen as the main entrance of cortical information to the 
circuitry of the basal ganglia, the STN also receives excitatory glutamatergic projections 
from the cerebral cortex (Bevan et a l, 1995; Kitai and Deniau, 1981). Thus STN have the 
morphological and neurochemical characteristics of pallidal terminals (Bevan et a l, 1995). 
This corticosubthalamic projection is exclusively ipsilateral and largely derived from the 
primary motor cortex with a minor contribution from prefrontal and premotor cortices. 
These projections are topographically organised. Corticosubthalamic neurons are mainly 
located in the layer V and many of them send axon collaterals to the striatum (Smith et a l, 
1998).
Thus the main input to the basal ganglia comes fr om frontal cortex and its output returns, via 
the thalamus, to the frontal cortex. The new information (program) is then transmitted via 
descending pathways to the lower level of motor control system in the brain stem and /or 
spinal cord course. Most motor programs are constantly adjusted during each manoeuvre to 
make the process perfect according to circumstances.
There are two connections (pathways) from the basal ganglia: 1) direct and 2) indirect, to 
the motor cortex /sensory motor cortex. The direct pathway produces the desired output 
activity by increasing and maintaining the initial activity and inhibiting unwanted 
movement through its influence via thalamus. It contains Di dopamine receptors, which 
control the direct pathway by reducing the inhibitory actions. The indirect pathway is
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responsible for sorting out unwanted motor activity by decreasing or submerging it. It 
contains dopamine D% receptors, which control the hyper-activity of striatopallidal 
neurons and subsequent reduction of the tonic inhibitory influence of the globus pallidus 
(GP) on the subthalamic nucleus (STN). The substantia nigra modulates the activity of 
the striatum. It activates the direct pathway, and inhibits the indirect pathway. But a 
damaged substantia nigra cannot maintain this balance. Lost or damaged neurons in the 
substantia nigra will cause loss of dopaminergic inneiwation, causing dominance of the 
indirect pathway, thus resulting in Parkinsonism or Parkinson like symptoms known as 
EPS.
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1.1.6. Neuro-transmitters and neuropeptides involved in EPS.
Neurotransmitter release is highly Ca^ "^  -dependent. Voltage sensitive Ca^ "^  channels are 
essential to transmitter release into the synapse. Membrane fusion that results in 
neurotransmitter secretion is the basis of neural communication.
A diagram illustrating the location of different neiuo-transmitters and neuropeptides in 
the basal ganglia is shown in Fig.2 (page-46). Details of the various neuro-transmitters 
and neuropeptides are summarised in the following sections.
Excitatory and inhibitory Amino Acids
The major excitatory neurotransmitter in the brain is glutamate (Glu). The major 
inhibitory neurotransmitter is y-aminobutyric acid (GABA). The corticostriatal pathway 
is excitatory via the amino acid transmitters, glutamate (Glu) and aspartate. GABA 
hyperpolarises cells rapidly, whereas Glu depolarises neurons rapidly. These amino acids 
mediate most of the fast synaptic transmission in the brain. These two amino acid 
neurotransmitter pools are not generally colocalised. However, in some brain regions, 
isolated neurons are seen in which GABA and Glu have reported. The excitatory 
neurotransmitter glutamate not only mediates point to point transmission, but also carries 
a more diffuse signal in the perisynaptic environment. Synaptically released glutamate 
can activate pre- or postsynaptic metabotropic receptors, many of which are located 
outside the synaptic cleft. Glutamate can also reach kainate or metabotropic receptors 
located on the GABA- releasing axons of intemeurons.
GABA is present in highly diverse inhibitory neurons and projection neurons throughout 
the brain. Cortico-striatal fibres terminate on medium spiny neurons, the output cells of 
the striatum. All the medium spiny neurons are inhibitory and release GABA.
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Approximately 95% of striatal neurons are thought to be GABA-ergic projection neurons. 
GABA co-exists with neuropeptides in various combinations in principal circuits and in 
intemeurons of the basal ganglia. The striatum has two different kinds of projections: a) one 
class projects directly to the output nuclei of basal ganglia; b) the other class projects 
indirectly to the output nuclei through external globus pallidus and subthalamic nucleus. 
GABA has been implicated in the regulation of dopamine-mediated events in the 
extrapyramidal system (Ossowska et al., 1984).
The synthesis of GABA requires a critical biosynthetic enzyme glutamic acid 
decarboxylase (GAD). GAD is the rate-limiting enzyme in the synthesis of GABA and 
catalyses the decarboxylation of glutamic acid to produce GABA. This enzyme is found 
exclusively in neurons in which GABA is neurotransmitter. GAD is not present in glia.
.Molecular cloning studies have shown that there are two isofonns of GAD - designated 
GAD65 and GAD67 according to their molecular weights, exhibit somewhat different 
intracellular distributions and are encoded by two genes, suggesting that the two isofonns 
may be regulated in different ways. These isoenzymes exhibit over 90% aminoacid 
sequence homology across the two species. GAD65 is more common in nerve endings and 
is particularly enriched in nerve terminals and thus may be somewhat more important for 
GABAergic transmission (Erlander et al., 1991). Morever, GAD67 is found in the 
cytoplasm. Increased demand for GAD67 usually involves the synthesis of new enzyme, as 
most of GAD 67 enzyme might be active and able to synthesize constant levels of GABA in 
GABA containing neurons (Soghomonian and Martin 1998). Glutamic acid is normally 
returned to neurons, where it regenerates GABA in the presence of GAD. Thus the presence 
of GAD67 is a marker for GABAergic neurons. Glutamatergic neurons do not use GABA as 
a transmitter (Erlander et al., 1991; Martin et al., 1993).
Both isofonns of GAD are expressed in GPi (entopeduncular nucleus, EN in rodent), SNR 
and GPe. GAD 67 mRNA expression changes in Parkinson’s disorder and also in 6 -OHDA 
lesioned rats.
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Thus GAD67 is an indirect marker of GABAergic activity within the basal ganglia. 
GAD67 mRNA expression has been taken as an index of the GABAergic activity in GPe 
neurons. Since GAD67 levels reflect long-term changes in GABA neurotransmission it 
could be used to detennine the steady-state level of GABAergic activity in GPe neurons 
in semi-chronic or chronic diseases of the basal ganglia (Levy et a l, 1997).
Catecholamines
In the brain, only 0.0005% of the cells use catecholamines as neurotransmitters. These 
belong to a wider group of neuro-transmitters, called monoamines. They are derived from 
amino acids. Catecholamines are metabolised by monoamine oxidase (MAO), which exists 
in two forms, MAO-A and MAO-B and by catechol-O-methyl transferase. Because most of 
the normal brain functions are so much dependent on tliese neurotransmitters and the 
neurons that contain them, enormous research efforts has been devoted on them as 
compared to other neurotransmitters.
The most prominent of catecholamine molecules are dopamine, noradrenaline and 
adrenaline neurotransmitters. Dopamine and noradrenaline are derived from tyrosine. 
Tyrosine hydroylase is the rate-limiting enzyme in catecholamine biosynthesis. The 
catecholamine biosynthesis is regulated by phosphorylation of at least four distinct serine 
residues by at least nine distinct protein kinases. Actions of synaptic catecholamine are 
terminated by specific transporter: the noradrenaline transporter and dopamine transporter. 
The uptake of catecholamines into synaptic vesicles for release is accomplished by distinct 
vesicular monoamine transporter proteins.
Although monoamine containing CNS neurons are concentrated in the brainstem, 
monoamine neurotransmitters exert modulatory effects on almost all circuits in the brain, 
acting to dampen or facilitate communication among neurons and to regulate the plasticity 
of these circuits.
Dopamine neurons have cell bodies in the midbrain within the substantia nigra pars 
compacta and the ventral tegnental area and in the hypothalamus. Dopamine (DA) is also
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produced by local circuit neurons in the retina. Both DA and L-DOPA (the precursor of DA) 
may cause changes in the metabolism and storage of serotonin in the brain. It is known that 
L-DOPA may accumulate in the serotonin nerve terminals and decreases the turnover of 
serotonin. On the other hand DA in the caudate nucleus can be reduced by large doses of 5- 
hydroytrytryptophan (5-HTP), the precursor of serotonin (5-HT). Thus DA may be 
displaced, or released from DA neurones by newly formed 5HT (Kostowski et al., 1972). 
Midbrain dopamine neurons projecting to the forebrain influence motor control, emotion, 
motivation and cognitive processes, including multiple forms of memory. Hypothalamic 
dopamine neurons regulate neuroendocrine function, most notably inhibiting the synthesis 
and release of prolactin.
There are only 12500 noradienaline containing neurons in the locus coeruleus in the 
human brain, and even fewer than these in rodent’s brain. But more and more, it is 
evident that they are very important for the overall function of brain. Noradrenaline is 
synthesised in a small number of brain stem nuclei, e.g., locus ceruleus in the dorsal pons. 
Noradrenaline is believed to play important roles in attention, learning, memory and 
many more physiological activities. These neurons have widely distributed axons that 
project to virtually every areas of the brain. Thus changes in the neuronal activity of these 
cells can alter noradrenaline release through vast areas of brain. Noradrenergic 
mechanisms have been implicated in the modulation of catalepsy, as noradrenaline 
hyperfunction antagonises the cataleptogenic effects of haloperidol (Toru et al., 1985) or 
EPS.
Adrenaline also occurs in a very small number of cells in CNS in the lateral tegmental 
region and in the dorsal medulla. These cells may be involved in the control of 
movement, although the functions of these cells are not well understood.
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Serotonin
Serotonin is the third major monoamine transmitter. It is also known as 5- 
hydroxytryptamine (5-HT). Serotonin is an indolamine that possesses a hydroxyl gioup at 
the 5 position and a terminal amine group on the carbon chain. It is synthesised from the 
amino acid tryptophan. Tryptophan is actively transported across the blood-brain barrier 
and hydroxylated by tryptophan hydroxylase producing 5 -hydioxytryptophan, which is 
then decarboxylated by L-aromatic amino acid decarboxylase (enzyme, that is also 
involved in the biosynthesis of catecholamines) and the end product is serotonin. 
Tryptophan hydroxylase is a rate-limiting enzyme. This enzyme also belongs to the same 
family of amino acid hydroxylase as tyrosine hydroxylase for catecholamine. Both these 
enzymes can be activated by protein kinase A, cAMP and also by a calcium / calmodulin- 
dependent protein kinase. Serotonin reuptake is mediated by a serotonin transporter. 
There is only one gene for the human serotonin transporter, with 48% homology to both 
noradrenaline and dopamine transporters at the amino acid level.
Neurons that synthesise and release serotonin (5-HT) are found almost exclusively in the 
raphe nuclei of the brain stem. The dorsal raphe and median raphe innervate much of the 
rest of the CNS by means of numerous and sometimes diffuse projection pathways.
Histamine
Histamine is produced in the posterior hypothalamus. Recent research indicates that it 
also serves important functions in the CNS. The neurons that produce histamine project 
to regions through the brain and spinal cord synaptically where it acts on at least three 
receptor subtypes. Areas that receive especially dense projections include the cerebral 
cortex, hypocampus, neostriatum nucleus accumbens, amygdala and hypothalamus. 
Many psychotropic medications including the antidepressants and antipsychotics 
(clozapine) cause sedation partly because they are potent histamine Hi receptor 
antagonists. Histamine is produced by the decarboxylation of the amino acid histidine by
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histidine decarboxylase, which is also involved in the synthesis of catecholamines and 
serotonin. Histamin has been implicated in the regulation of perception of pain, 
prevention of emotional sickness. However actions of this neurotransmitter in the nervous 
system not yet clearly understood.
Acetylcholine
Acetylcholine was the first molecule to be identified as neurotransmitter. Acetylcholine is 
produced in the CNS by projection neurons, whose cell bodies are located in the basal 
brain stem and basal forebrain. Ach is also synthesised in intemeurons in many brain 
regions including the striatum. The basal ganglia receive cholinergic input from the 
nucleus basalis, the pedunculopontine nucleus and laterodorsal tegmental nucleus. 
Innervation is intrinsic. Innervation in this region also arises from large cholinergic 
intemeurons, which are critical components o f the complex circuitry that underlies 
extrapyramidal motor control.
In normal condition, there is a balance between cholinergic and dopaminergic systems in 
the basal ganglia. And an enhancement of the cholinergic component might yield an 
inhibition of dopaminergic neurotransmission causing catalepsy in animals.
Nitric oxide
Nitric oxide (NO) is an endogenously synthesized effector molecule which acts as a 
neurotransmitter with novel properties in the central and peripheral nervous systems. It is 
a free radical. Its involvement as a mediator o f cell death in neurodegenerative diseases is 
well known. In the central nervous system, nitric oxide synthase (NOS) is expressed in
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select neural populations. NOS distribution in the brain regions are detected in 
subthalamic nucleus, putamen, caudate nucleus, globus pallidus, claustrum and 
overlaying insular cortex. NOS positive neurons were not found in the substantia nigra 
and no signal was detected in the thalamic levels. In subthalamic nucleus, more than 95% 
of neui’ons express NOS mRNA. Whereas in the caudate and putamen only 1.5 -  2% of 
the total neurons express NOS mRNA. Because of its specific distribution, NOS mRNA 
expression can be used as a marker gene for the subthalamic nucleus and the striatum.
Neuropeptides and calcium binding proteins
Neuropeptides are small proteins that serve neurotransmitter like functions in the nervous 
system. They serve primarily modulatory roles in the nervous system and usually interact 
with G- protein coupled receptors. Synthesis o f neuropeptides requires the transcription of 
DNA and translation of the resulting mRNA into protein. The receptors for neuropeptides 
bind to their ligand with much greater affinities than do the receptors for small-molecule 
transmitters.
Neuropeptides are synthesised differently than neurotiansmitters, as large precursor 
polypeptides that undergo extensive post-translational processing that includes cleavages 
into smaller peptides, the prepropeptide and subsequent enzymatic modification into an 
active peptide. Tachykinins, a family of neuropeptides’ has several members derived from 
two preprotachykinin genes. Neurokinin A and B, and substance P are members of this 
family.
The medium spiny neurons contain several neuropeptides:
a) Tachykinin system: - Substance P and neurokinin A and B
b) Opioid system:-Dynorphin and Enkephalin
Expression o f these substances is regulated by the dopamine input to the striatiun. 
Substance P and dynorphin are the co-transmitters with GABA in medium spiny neurons
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in the direct pathway from the striatum. These cells of the direct pathway contain 
dopamine Di receptors. Enkephalin is the co-transmitter with GABA in the medium 
spiny neuron derived indirect pathway to the external globus pallidus. These cells express 
dopamine D2 receptors.
The distribution of calbindin D-28k (CB) and parvalbumin (PV), two calcium binding 
proteins, in the neurons and fibres in the mammalian central nervous system has been 
widely investigated (Baimbridge, et.al. 1992; Celio, et.al. 1990; Hontanilla et al., 1998; 
Munkle et al., 2000;). In the central nervous system, the two proteins CB and PV occur 
mostly in the neuronal populations that are involved with specific calcium -  dependent 
mechanisms. GABAergic neurons from different brain regions contain high levels of 
parvalbumin. Calcium-binding protein parvalbumin is preferentially associated with 
spontaneously fast-firing, metabolically active neui'ons and coexists with gamma-amino- 
butyric acid (GABA) in cortical inhibitoiy intemeurons. Parvalbumin is a slow 
Ca^ri)uffer that may affect the amplitude and time course of intra-cellular Ca^^transients 
in terminals after an action potential, and hence may regulate short-term synaptic 
plasticity.
The protein CB occurs in the striatonigral pathway that undergoes degeneration in some 
of the neurodegenerative diseases (e.g., Huntington’s disease). The protein CB is mainly 
involved in the intracellular calcium homeostasis.
Parvalbumin on the other hand, is only associated with fast - firing neurons. It helps 
specific neurons to maintain a fast-firing rate by reducing the Ca dependent potassium 
outflow, responsible for ‘after hyperpolarisation period’. Thus PV containing neurons 
have a high metabolic rate. PV containing intemeurons are among the very few cells that 
can survive certain degeneration.
PV positive cells are present in the number of basal ganglia structures; striatum, globus 
pallidus and substantia nigra (Munkle et al., 2000)
44
Heat shock proteins
Heat shock proteins (hsp) belong to an extensive family of proteins. Heat shock and 
related proteins are major component of the central nervous system response to metabolic 
stresses. They act as chaperones, the proteins that bind to and stabilise an otherwise 
unstable conformer of another protein. By controlled binding and releasing of the 
substrate under physiological conditions, hsp facilitate molecule’s correct fate: folding, 
oligometric assembly and transport to a particular subcellular compartment, or controlled 
switching between active/inactive conformations, thus limit protoxicity (Hendrick and 
Haiti, 1993). Some members of the hsp family are induced and over expressed under 
stress conditions in a wide variety of systems including brain, and are thought to exert a 
protective function (Lindquist, 1986). Thus, induction of these proteins in the brain, have 
been interpreted as a marker of cellular injury (Gonzalez et al., 1989; Sharp et al., 1991).
grp75 is a mitochondrial hsp 70- family member of stress proteins in the rat brain (Massa 
et al 1995). grp75 has been implicated in transport of proteins across the mitochondrial 
membrane and their stabilization prior to final folding. grp75 is expressed following 
metabolic stress in rat brain and induced by a calcium ionophore and glucose deprivation. 
grp-75 is regulated in response to the altered activity in the indirect pathway, induced 
under stress condition such as lesions and is thought to exert a protective function .
When the degree o f injury is small, induction occurs in the area of injury, similar to that 
for hsp70. But when the injury is extensive, grp75 is up regulated in the neurons outside 
the injury. The induction of grp75 may represent a sensitive marker of metabolically 
compromised tissue and drug related change in the brain.
grp 75 is highly expressed in the reticular and subthalamic nucleus, globus pallidus and 
amygdala.
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Fig.2. Schematic presentation of basal ganglion micro-circuitry with their neurotransmitters 
and neuropeptides.
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1.1.7. Receptors in Basal ganglia
A diagram illustrating the location of different receptors in the basal ganglia is shown in 
Fig. 2 (page-46). Details of the various receptors and their subtypes are summarised in 
the following sections.
Glutamate receptors
Glutamate receptors are classed into two groups: a) ionotropic receptors and b) 
metabotropic receptors.
There are three classes of ionotropic glutamate receptors: 1) N-methyl-D-aspartate 
(NMDA), 2) a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and 3) 
kainate. There are eight metabotropic glutamate receptors: mGluRl-mGluRS. These are 
again grouped into three groups: Group 1 (mGLu R1 & mGlu R5); Group 11 (mGlu R2 
& mGlu R3); Group 111 (mGlu R4, mGlu R6 , mGlu R7 & mGlu R 8 ). Several types of 
mGluRs are located on the presynaptic terminals of central neurons.
GABA Receptors
GABA receptors are divided into two main groups:
The ionotropic GABAa receptor is a heterooligomeric protein complex that consists of a 
GABA binding site coupled to an integral Cl “ channel. GABA a is the site of action of 
anxiolytic benzodiazepines and other sedative hypnotics. They are considered as 
metabotropic.
In hippocampus, thalamus and cortex, low- intensity stimulation of inhibitory 
intemeurons causes inhibitory postsynaptic potentials that are mediated entirely by 
GABAa receptors. GABAb receptors are expressed on both pre and post-synaptic 
membranes and like other Gi linked receptors, open K channels and decrease Ca 
conductances, and inhibit adenylyl cyclase.
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Postsynaptic GABAb receptors produce a slower but longer lasting inhibition, but require 
much longer stimulation and / or higher frequency.
Low doses of G ABA -  mimetic stimulate presynaptic receptors. This would result in an 
anticholinergic effect, restoring the chemical balance of the striatum, and thus 
diminishing the EPS effects o f antipsychotic drugs. High doses of GABA- mimetic 
would stimulate the postsynaptic GABAergic receptors, resulting in a blockade of 
dopaminergic transmission, and thus reinforcing the anti-dopaminergic effect of the 
neuroleptic and EPS. Thus modulation of glutamate (principal excitatory 
neurotransmitter) and GABA (principal inhibitory neurotransmitter) receptors is of 
paramount importance for many brain functions and dysfunction of the GABA system 
may be a major contributory factor in the pathology of schizophrenia (Ossowska et al., 
1984).
Dopamine Receptors
Molecular and pharmacological studies reveal that there are at least five distinct 
dopamine receptors: Di, D2, D3, D4, and D5. All catecholaminergic receptors belong to 
the G-protein coupled receptor superfamily.
The dopamine receptors are classified into two main classes: 1) Di -  like, consists of D; 
and Ds and 2) D% -  like, consists of D2, D3 and D4 receptors. Both the two classes of 
receptors exert their biological activity by activating G-proteins after coupling with them. 
Di dopamine receptors interact with Gs complexes resulting in the activation of adenylate 
cyclase and an increase in intracellular cAMP levels. Whereas the D2 dopamine receptor 
interacts with Gi complexes to inhibit cAMP production and considered not to be linked 
to the adenylate cyclase.
1) Di receptors are ten times more abundant in brain than D2 like receptors. D% receptors 
are expressed predominantly by pyramidal neurons on their dendritic spines, which
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aie an ideal location for modulation of the glutamate-mediated inputs to tliis. Di 
mRNAs are also found in high levels in the caudate-putamen and nucleus accumbens.
2 ) D2 receptors are present in very high numbers in caudate-putamen, the nucleus 
accumbens and substantia nigra. They are expressed in the pyramidal cells as well as 
in the GABA-containing interneurons (local-circuit neurons) and glutamate- 
containing nerve terminals that innei-vate the region. D2 receptors are a major site of 
action o f typical antipsychotic dmgs.
D2 receptors often serve as autoreceptors because their activation can inhibit the cells 
in which they reside. Dopamine release from a nerve terminal can activate D2 
receptors present in the presynaptic terminal and can reduce the synthesis or release 
of more dopamine. Thus, D2 receptor acts as a negative feedback mechanism to 
modulate or terminate dopamine signaling at a particular synapse.
The cur rent concept about functional organisation of the basal ganglia suggests a 
critical role for D2 receptors and the indirect pathway in the pathophysiology of EPS. 
It had been shown that D2 receptor-deficient mice lacking either one or two functional 
copies of the D2 receptor showed deficit in movement initiation, although they have 
normal movement speed, no postural abnormalities and no tremor (Murer et al., 
2000). There is a good corr elation between antipsychotic activity and affinity for the 
D2 dopamine receptor subtype for a wide range of dopamine receptor antagonists. 
The neuroleptics with less inhibitory action on the nigrostriatal dopamine system 
produce less cataleptic behaviour and cause much lower incidence of extrapyramidal 
symptoms. A selective deficit in D2 receptor mediated dopamine actions could lead to 
the development of some specific neurochemical changes in the basal ganglia indirect 
pathway in the Parkinson like side effects of antipsychotic drugs.
3) D3 receptors are found mostly in the Islands of Calleja and in the nucleus accumbens 
and cerebellum (Sokoloff et. a l , 1992a).
4) D4 receptors are found in frontal cortex, midbrain area, amygdala, hypothalamus, and 
thalamus.
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5) Ds mRNA is only present in the hippocampus, hypothalamus and paraphasicular 
nucleus of the thalamus.
All existing antipsychotics possess dopamine receptor antagonistic properties.
Noradrenaline and adrenaline Receptors
As in all catecholaminergic receptors, these receptors also belong to G protein-coupled 
receptor super family.
Adrenergic receptors are divided into a and p categories, both of which comprise many 
receptor subtypes. Each subtype responds in varying degrees to both noradrenaline and 
adrenaline. All p receptors are Gs -coupled, and most a  2 receptors are Gi -coupled, 
functioning not only as heteroreceptors but also as autoreceptors for catecholaminergic 
neurons. The adrenoreceptor has also been suggested as a possible candidate involved 
in the atypical clinical profile of ADP like clozapine (Wadenberg and Hicks, 1999)
Serotonin Receptors
Fourteen distinct serotonin receptors have been cloned so far, and are classified into 7 
receptor families. Pharmacologically and functionally, there is greater understanding of
5-HTl, 5-HT2, 5HT3, and 5HT4 families than the 5-HT5, 5HT6 and 5HT7 subtypes. All 
5HT receptor families are all G-protein coupled receptors with the exception of 5HT3 
which is ligand gated ion channel coupled (Kinsey et a l, 2001). 5-HTl receptors couple 
with Gi protein; 5-HT2 couple with Gq protein; and 5-HT4, 5-HT6, 5-HT7 receptors are 
coupled to Gs protein; coupling for 5-HT5 has not been deteiinined.
The serotonergic 5-HTl A receptor is termed a somatodendritic autoreceptor because it 
resides on serotonergic cell bodies and dendrites. Its activation reduces cell firing and 
reduces the synthesis and release of serotonin. Serotonergic 5-HTlD (in human)
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receptors and 5-HTlB (in rodents) receptors decreases the local synthesis and release of 
transmitter. 5-HTl A and 5HT1D receptors are highly homologous and both signal by 
coupling to Gi proteins.
Out of all these 5-HT receptors 5-HT2 aroused interest amongst neuroscientists because 
of the high affinity of atypical antipsychotics for 5 HT2c receptors. This fact further 
suggests that this receptor may play a role in the antipsychotic activity of these agents 
and may have possible role in the action of atypical neuroleptic drugs.
Most of the atypical antipsychotic drugs, clozapine, risperidone, olanzapine, quetiapine 
and some other atypical neuroleptic drugs target other neurotransmitter receptors along 
with dopamine receptors, such as 5HT receptors (Barnes and Sharp 1999; Bymaster et al., 
1996; Kapur et al., 1999; Meltzer, 1989,1991; Pilowsky et al 1992; Stockmeier et al 
1993; Sebens et al 1998; Tandon, 1970; Wadenberget al., 1997). These compounds have 
considerable affinity for the subgroups of 5 HT2 receptors such as 5 -HT2a, 5 HT2b and 
5HT2C. Amongst these, 5 HT2c have been suspected to have influence in the motor control 
and EPS. Affinity for 5 HT2b receptor for these drugs could be significant in producing 
EPS, but not very much is known about this yet.
These 5 -HT2c receptor is a prominent serotonin receptor systems, was found in the brain 
areas such as; basal ganglia (Wolf and Schütz 1997) substantia nigra (pars compacta and 
reticulata), globus pallidus, cerebral cortex (pyriform, frontal and cingulate cortex) and 
olfactory tubercle, nucleus accumbens, caudate-putamen, amygdala and thalamus. They 
are also found in raphe nuclei and in adjacent reticular nuclei, suggesting that 5HT2c 
receptors may function as autoreceptors on serotonergic neurons (Eberle-Wang et al., 
1997; Palacios et al., 1990; Pasqualetti et al., 1999; Pompeiano et al, 1994; Stefulj et al., 
2000).
The 5 HT2C receptors are known to have both high and low agonist affinity states. It had 
been suggested that the interaction of serotonin with the low affinity state of 5 HT2c
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receptors are responsible for signal transduction. Activation of 5HTzc receptors induces 
an increase in intracellular calcium and a calcium -induced current.
Although the physiological roles of 5-HTic are not completely known, administration of 
5 HT2C receptor agonists can influence locomotion, feeding behaviour, body temperature, 
hormone secretion, and produce anxiogenic effects (Kennett et al., 1989). This receptor 
has also been implicated in obsessive compulsive disorders and migraine (Curzon and 
Kennett, 1990).
Acetylcholine receptors
Acetylcholine (Ach) receptor elicits its effects in the CNS by means of two different 
classes of receptor systems: a) nicotinic receptors, which are ligand-gated channels, and
b) muscarinic receptors, which are from the G protein-coupled receptor superfamily.
The activation of nicotinic Ach receptors by Ach leads to the rapid influx o f Na^ and Ca^ 
and subsequent cellular depolarisation.
All five muscarinic receptor subtypes (Caulfield and Birdsall, 1998) are expressed in the 
brain, and can be subgrouped based on their patterns of G protein coupling; M l, M3, and 
M5 receptors couple with Gq proteins. M2 and M4 receptors couple to Gi proteins 
(Birdsall et al., 1983; Burstein et al., 1997). M l, M3 and M5 receptors produce their 
effects by stimulating or inhibiting activation of the phosphatidylinositol system. As like 
most Gi -linked receptors, M2 and M4 receptors elicit mostly inhibitory responses. They 
act by activating inwardly rectifying K^channels, inhibiting voltage gated Ca  ^channels, 
and inhibiting adenylyl cyclase (Zhang and Bymaster, 1999). M l, M2, M3, and M4 
receptors are present in the substantia nigra. M l, M3 and M4 receptors are located in the 
cerebral cortex and hippocampus, where their activity may mediate some of the effects of
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Ach on learning and memory (Felder, 2000; Eglen et al., 2001). M l and M4 subtypes are 
believed to mediate cholinergic signaling in extrapyramidal motor circuits. M2 receptors, 
which are least abundant, are concentrated in the basal forebrain, the site of several 
cholinergic nuclei. It is believed that they may act as autoreceptors to control Ach 
synthesis and release from forebrain cholinergic neurons. M5 receptors are least abundant 
of the muscarinic receptors and are scattered through out the brain.
Histamine Receptors
Three histamine receptors have been identified; Hi, H%, FI3. All are G- protein coupled 
receptor super family. Hi couple to Gq proteins and H2 receptors couple to Gs proteins; H3 
coupled to Gi proteins and may act as autoreceptors, functionally analogous to the a- 
adrenergic, dopamine D2 and 5-HTi receptors. The H3 receptor also functions as 
heteroreceptors and regulates the release of other neurotransmitters from nerve terminals. 
Many drugs that cause drowsiness contain H] receptor antagonists as active ingredients, 
which can cross blood brain barrier. Newer medications are non sedating because they do 
not cross the blood-brain barrier. Olanzapine and Y931 also have high affinity for Hi 
receptors.
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Neuropeptide Receptors
There are many neuropeptide receptors. Some neuropeptides binds with only one known 
receptor, wliile others bind to more than one receptor subtypes. Similarly, some 
neuropeptide receptors have the ability to bind more than one peptide.
The presence of neuropeptide receptors in the basal ganglia parallels the presence of the 
corresponding neuropeptides, with high levels of opioid, tachykinin, somatostatin and 
NPY receptors, plus many others at lower levels.
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1.1.8. INVESTIGATION OF THE ANOMALOUS LOW INCIDENCE 
OF MOTOR SIDE EFFECTS OF THE COMPOUND -  Y931
The compound Y-931 (8-fluoro-12- (4-metliylpiperazin-l-yl)-6H"[l] benzothieno [2,3-
b][l,5] benzodiazepine maleate} is a new potential atypical antipsychotic drug (Morimoto et 
a l, 2000). It is classed as a multi-affinity receptor target agent similar to clozapine and 
olanzapine. Y-931 interacts with receptors such as dopaminergic, serotonergic, a-adrenergic, 
muscarinic and histaminergic receptors. In models of N-methyl-D-aspartate (NMDA) 
receptor activity, Y-931 demonstrated the most potent protective action against the 
dizocilpine-induced neurotoxicity (neuronal vacuolization) in the rat retrosplenial cortex 
(Morimoto et a l, 2002). It reportedly gives veiy few (if any) extra pyramidal side effects 
(EPS) in animal models at equivalent doses (MPC unpublished data).
Y931 has a similar receptor - profile to clozapine and olanzapine, that is, high affinity for 
Da, 5-HT2c, 5-HTô, 5-HT?, a-Adreno-receptors, mACh, muscarinic receptors M l, M2, M3, 
M4, M5, and Histamine HI (MPC unpublished data). The overall aim of this study was to 
investigate the mechanisms responsible for the lack of EPS during Y931 treatment, despite 
significant affinity of the drug for Da receptors.
Three hypotheses can be suggested, based on the current knowledge of Y-931 
pharmacology, and on the premise that Y-931 blocks striatal Da sites in sufficient levels 
to cause EPS, but also acts at other sites in the CNS to prevent the expression of EPS.
1) Y-931 acts within the striatum to suppress the activation o f the indirect 
pathway, despite blocking striatal Da dopamine receptors. The antagonist 
actions of Y-931 at muscarinic receptors in the striatum could be involved, 
acting to suppress the EPS via the suggested interaction between muscarinic 
and Da dopamine receptors in the striatum.
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2) Y-931 acts outside the striatum to suppress the activation of the indirect 
pathway. Via its relatively high affinity for S-HTac or muscarinic M3 
receptors, Y-931 may act to suppress EPS at a site downstream of the 
striatum. Muscarinic M3 receptors increase STN activity, so antagonism at 
this receptor may act to suppress the abnormal stimulation of the indirect 
pathway following blockade of striatal Da receptors. Also, SHTac receptor 
antagonism suppresses STN activity, so the SUTzc receptor antagonist 
properties of Y-931 may be involved in reducing EPS.
3) Y-931 acts to elevate the activity of the direct pathway. Y-931 may facilitate 
stimulation of nigrally projecting neurons in the striatum by the motor cortex 
via a facilitation of glutamatergic NMDA receptor activation. The direct 
pathway from the striatum to the SNr could show increased activity in 
response to Y-931 relative to the indirect pathway.
Neurochemical markers of neuronal activity (iimnediate early genes and GABA neuron 
markers) will be employed for the analysis of above hypothesis. In addition, the role of 
5HT2C/2B receptors in modulating the neurochemical changes and in modulating 
haloperidol-induced catalepsy will be investigated.
1.1.9, Aims of this thesis
In the studies presented in this thesis, the aim is to compare the regional neurochemical 
effects of Y931 with olanzapine, an atypical antipsychotic drug and with the conventional 
antipsychotic drug haloperidol. This will enable the determination of any distinctive 
characteristics of Y931 in the basal ganglia-thalamocortical neuronal pathways, to 
explain its anomalous behaviour in exhibiting very few (or, any at all) EPS.
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CHAPTER 2: Comparison of the effect of acute 
treatment with haloperidol, Y931 and olanzapine on 
immediate early gene expression and some of the 
marker genes of the motor circuits in the rat basal 
ganglia.
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2.1. Introduction
Effect of acute treatment with haloperidol and Y931 on immediate early 
gene (lEG) expression and some of the marker genes of the motor 
circuits in rat basal ganglia: Study of Immediate Early Gene expression 
to characterise Y- 931.
Immediate early genes are a unique class of genes. Transcription of these molecules can be 
activated witiiin minutes and characteristically their induced transcription is very short-lived. 
They are also expressed at unusually low levels basally. The c-fos and c-mycoproto -onco­
genes were some of the immediate early genes that were first discovered (Greenberg and 
Ziff 1984). The rapid accumulation of these products combined with histological methods 
that offer detection at the cellular level are key features that have led to their wide use in 
visualizing activated neurons.
Many lEGs have been identified in the brain. They are divided into families depending on 
their structural similarities. The members o f fos- or jun families are closely related to c-fos 
or c-jun. There are also some lEGs, which are structurally unique, such as zif-268, a zinc 
finger containing protein (Millbrandt, 1987).
Immediate early genes (lEGs) act as transcription regulatory factors by coordinating 
changes in gene expression as they encode transcription factors. lEG induction has been 
widely investigated in relation to the mechanism of action of antipsychotic drugs (Sebens 
et. al., 1998). Inducible transcription factors, including certain immediate early genes, 
may mediate between receptor-activated second messenger systems and expression of 
genes involved in the differentiated functions of neurons.
All clinically effective APDs have high affinity for dopamine receptor, specifically for D2 
receptors, c-fos is believed to be an initiator of several biological adaptations. And all 
clinically effective APDs induce the lEG c-fos and its protein product Fos in the forebrain of 
mammals with a characteristic regional pattern of expression. Typical and atypical
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antipsychotic drugs are known to elevate the level of certain lEGs in certain areas of brain. 
Antipsychotic drugs with dopamine D2 antagonist properties, such as haloperidol, induce 
both c-fos and zif 268 mRNA in caudate-putamen. But, atypical antipsychotic drugs, e.g., 
clozapine, induce zif268 but not c-fos mRNA in that region (Nguyn et al., 1992). After 
treatment with specific antipsychotic drugs, such as haloperidol, olanzapine and Y931, the 
expression level of zif 268, c-fos and fra-2 mRNA (the most investigated IBGs) in different 
areas of brain should give an idea, how differently these APDs act in different areas of brain. 
And how Y931 could modulate the activity of direct and indirect pathways in basal ganglia 
through which it could ameliorate EPS.
Both the Fos and Jun family of nuclear phosphoproteins may group together to form homo - 
or heterodimeric AP-1 (activator protein-1) complexes. This complex (AP-1) then activates 
protein kinase C to mediate transcriptional responses. The content of AP-1 may vary under 
different physiological conditions. Closely related members of the same family may 
contribute to quite distinct biological phenomena. These complexes then bind to a DNA 
consensus sequence that is known to be present in numerous gene promoters. After binding 
to the gene, AP-1 may either activate or repress the candidate gene. Thus AP-1 complexes 
are indispensable in the regulation of neural gene expression by extracellular signals.
Zif 268 belongs to the zinc -finger class of transcription factors. The protein contains finger- 
like protrusions that are stabilised by ionic zinc, which act directly on the regulatory 
sequence GCGG/TGGGCG. The presence of zif268 at the promoter site serves to modulate 
the expression of the target gene. Thus both the c-fos and zif268 act as third messengers in 
activating the target genes.
fra-2 is a late expressed fos related lEG gene found mainly in the cerebral cortex and in 
thalamus, fra-2 mRNA is expressed later than c-fos and zif-268 and persist long after 
most o f TEG mRNA expression is lost. It had been shown that dopamine lesions induce a 
prolonged expression of Fos-related antigens (FRA’s) in the striadopallidal neurons, 
which are known to contain D2-dopamine receptors. FRA’s are members of the leucine- 
zipper family of transcription factors that regulate neuronal gene expression. FRA’s must
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dimerise with the Jun-family for DNA-binding activity. Di-dopamine receptor 
antagonists also induce FRA’s in the striatal neurons (Dragunow et. al., 1995).
Some studies have shown that glutamate binding to the NMDA receptor can induce both c- 
fos and zif268. It has also been reported that the opening of the voltage sensitive calcium 
channels could trigger c-fos expression after activation of AMPA-kainate receptors by 
glutamate. In either condition ionic calcium is recognised as a major mediator of induction 
of both AP-1 transcription factors and zif268 gene (Robertson and Fibiger, 1996).
In the present studies, the pattern of gene activation of c-fos, fra-2, zif-268- member of 
immediate early genes and GAD67 (Glutamic acid decarboxylase 67), grp-75 (glucose 
regulating protein, a relation of heat shock protein group hsp-72), NOS (Nitric oxide 
synthase) and parvalbumin - some of the marker genes of motor circuits in basal ganglia, 
will be investigated using in-situ hybridisation. After treatment with Y931, haloperidol and 
other drugs, in situ hybridisation may reveal the regional sites of activity of these drugs and 
Y931, from which we may be able to gain information on how Y931 could work giving less 
or no extrapyramidal side effects.
A potential drawback of using in-situ hybridisation is, tlie experimental animals need to be 
carefully treated to have minimal stress during the procedure, as this may cause lEG 
expression. But, with appropriate controls, lEG induction should provide good indication of 
the brain regions affected by the drug treatment.
2.2.Aim.
The aim of the studies presented in this chapter, was to determine whether haloperidol, 
Y931 and olanzapine produce distinct patterns of mRNA expression of immediate early 
gene (ÏEG) expression and expression of NOS, GAD 67 and grp 75 mRNAs in the 
different regions of rat brain.
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2.3. Material and Methods
Drug treatment:
Name of the drugs Source Dosage
1. Haloperidol RBI 1 mg / kg
2. Y931 Welfide Corporation 1 0  mg / kg
3. Vehicle 
[0.5% (HPMC)] Welfrde Corporation 1m l/k g
Table 4. Drugs used for the acute treatment study.
24 male hooded Long Evans rats (235-295g) were purchased from Harlan-Olac, UK. 
Animals were housed under a 12 hour light /dark cycle with free access to food and drink. 
Animals were divided into three groups at random. Eight animals were in each group.
Group A = Vehicle (0. 5%HPMC)
Group B = haloperidol (1 m g/ kg)
Group C = Y931 (10 mg / kg)
On the day of treatment, the animals were injected intra-peritoneally (i.p.) with vehicle 0.5% 
hydroxypropylmethylcellulose (HPMC), 1 ml/kg of body wt., haloperidol (Img / kg) or 
Y931 (10 mg / kg). We are using Y931 at this dose because of its antipsychotic property 
such as inhibition of apomorphine induced hyperactivity and suppression of conditioned 
avoidance response (CAR) at this dose (Morimoto at al., 2002). Animals were randomly
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allocated to treatment groups. Forty-five minutes after injection each rat was killed by 
decapitation. Brains were quickly removed and frozen in iso-pentane cooled to -  42^C on 
dry ice. Brains were coated with embedding medium (Lipshaw) and stored at -70^C until 
required.
All animal experiments were carried out in accordance with the U. K. Animals (Scientific 
Procediues) Acts, 1986 and related guidelines.
20 pm coti'onal sections were cut from four different levels of each brain. Sections for each 
level were taken according to ‘ The Rat Brain’ atlas (Paxinos and Watson, 4^' Edition. 
1995). Each level was as follows:
Level 1 (Plate-12): visualising-1) accumbens shell and core, 2) cingulate cortex area 
1&2, 3) primary motor cortex and secondary motor cortex and 4) caudate putamen 
(striatum).
Level 2 (Plate-24); visualising- 1) somatosensory cortex (area 1 and 2), 2) caudate 
putamen and 3) lateral globus pallidus.
Level 3 (Plate 36): visualising- 1) retrosplenial agranular cortex, 2) subthalamic 
nucleus, 3) para subthalamic nucleus.
Level 4 (plate 42): visualising- 1) substantia nigra pars reticulata, 2) substantia nigra 
pars compacta, 3) substantia nigra, lateral part.
The above areas are displayed in fig.3. (Page: 63-64)
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M I
CPu
Acb
Plate -12 (Paxinos & Watson, 4^ Edition 1998); showing striatum (Cpu), Accumbens Core 
& shell (AcbC & AcbSh), Cingulate cortex- land Cingulate cortex-2, Motor Cortex-1 and 
motor cortex-2.
CPU
LGP
Plate -24 (Paxinos & Watson, 4^ Edition 1998): showing striatum (Cpu), Lateral globus 
pallidus (LGP), Sensory Motor cortex-1 and 2 (SI, S2)
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J
Plate -35 (Paxinos & Watson, 4* Edition 1998): showing subthalamic nucleus (STh / STN) 
and retrosplenial cortex, agranular (RSA).
Plate -42 (Paxinos & Watson, 4* Edition 1998): showing -Substantia nigra pars reticulata 
(SNR), Substantia nigra pars compacta (SNCD).,Substantia nigra. Lateral part (SNL), 
Retrosplenial cortex, agranular (RSA).
Fig: 3. Schematic representation of brain levels in which sections were collected for in situ 
hybridisation (taken from Rat Brain in stereotaxic co-ordinates, 4^ Edition, Paxinos and 
Watson 1998).
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Two sections from the same level of each brain and sections from two animals were placed 
on one poly-L-lysine coated slide (previously baked at 180° C and coated in a 0.01%poly-L- 
lysine solution made up in DEPC treated water). Slides were labelled appropriately. Some 
sections were also cut from control animal brains at the same levels for use as controls. A 
LEICA CMl 850 cryostat at -20® C was used for cutting the sections. Sections were dried at 
RT then fixed briefly in freshly prepared 4% (w/v) paraformaldehyde in phosphate buffered 
saline (PBS). After rinsing, the sections were sequentially dehydrated in 70%, 95% and 
absolute alcohol and then stored under absolute alcohol at 4®C.
2.3.1. In situ hybridisation (Wisden and Morris, 1994)
In-situ hybridisation is used for tracing the regional sites of gene expression in the tissue. A 
radiolabelled nucleotide tagged nucleic acid probe is allowed to hybridise directly to a tissue 
section, where it recognises its cognate mRNA and forms a probe -  mRNA complex. 
Excess probes are then washed off and tissue section is then exposed for autoradiography to 
reveal the sites on the tissue section, treated by the probe.
There are many different types of probes, e.g.. Oligonucleotides, cDNA probes, cRNA 
probes. Oligonucleotides are most commonly used probe as different oligonucleotides could 
be distinguished easily differing in small regions of nucleotide sequences in their mRNA. 
The technique for using this probe is simple and does not need very much previous 
molecular biology experience.
Oligonucleotide probes of unique sequence were used for in-situ hybridisation (ISH). 
These were:
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1) zif-268 (45 mer) 5' CCG TTG CTC AGC AGC ATC ATC TOC AGT TTG GGG 
TAGTTGTCC 3'
Complementary to nucleotides spanning amino acids sequence 2 - 1 6  (Millbrandt, 1987)
2) c-fos (45 mer) 5 ' CTG GAG CCA TCT TAT TCC TTT CCC TTC GGA TTC TCC 
GTT TCT CTT3'
(C uiranetal, 1987)
3) GAD 67 (45 mer) 5' GCA TCC ATG GGC TAG GCC ACA CCA AGT ATC ATA 
TG TTG TA G G A CG3'
4) NOS (45 mer) 5'GGC CTT GGG CAT GOT GAG GGC CAC TAG CCA GAG CTG 
TGA CTCTG T3'
All the above oligonucleotides were purchased from GenBank, UK.
4) grp 75 (45 mer) 5 ' AAC AAC TGC ACC CTT GAT TGC TTC TGA CGC ATA ATC 
CCTTCT TGA 3'
The above probe was purchased from Thermo Hybaid GmbH, Germany.
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Labeling of oligonucleotide probe:
35,Probes were end-labelled with deoxynucleotide transferase (TdT) in presence of SdNTP
35,(46.3 MBq / ininol) in TdT buffer. Molar ratio of SdATP to oligonucleotide was 30:1.
Name of the reagent Source
1. Isopentane Fisher Chemicals, Loughborough UK.
2. Terminal deoxyneucleotidyle 
Transferase (TdT enzyme)
Boehringer Mannheim, Lewes UK.
3. TdT tailing buffer Amersham phannacia Biotech, Herts UK.
5. Diethyl pyrocarbonate (DEPC) Sigma, Poole UK.
6 . Dithiothreitol (DTT) As above
7. Paraformaldehyde As above
8 . Poly adenylic acid As above
9. Sodium Phosphates British Biochemicals International (BDH)
10. Sodium pyrophosphate As above
11. Glacial acetic acid As above
12. Dextran sulphate Amersham Life Sciences UK.
13. Formamide Fluka, Poole UK.
14. a-[ ]dATP New England Nuclear, Hounslow UK
15. Qiagen QLAquick Nucleotide 
Removal kit
Qiagen Ltd, Sussex UK
Table 5. Reagents for labelling Probes and in situ hybridisation. All the stock solutions 
for in situ hybridisation were made and autoclaved / sterile filtered and kept in small 
aliquots at the appropriate temperature.
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This reaction initiates the reaction for the formation of single stranded DNA from the 3‘ 
terminal. Reaction mix for this was as shown in the table 6 .
DEPCH2 0 0 .6  pi
TdT tailing buffer 1 .2  pi
Oligonucleotide 1.5 pi
“ SdNTP 1.5^1
TdT enzyme 0 .6  nl
Total vol. 5.4 Ml
Table 6 . Reaction mix for labelling
The mixture was incubated in a 37® C water bath for 1 hour. The reaction was then 
terminated by adding 60 pi of DEPC treated water.
To remove the un -incorporated nucleotides, Quagen QIAquick Nucleotide Removal kit was 
used according to manufacturer’s instructions. The extent of probe labelling was assessed 
using p-scintillation counting. Probes labelled from 10® to 3x10® d.p.m / pi "^were used for 
in situ.
Labelled probe was then stored at -20® C after adding 2 pi IM DTT.
On the day of the in situ hybridisation experiment, sections were removed from absolute 
alcohol and allowed to air dry for 30 mins. Then the sections were hybridised with selected 
probes as follows:
The radiolabelled probe was diluted 1:100 with hybridisation buffer [50% deionised 
foimamide, 2% 5mg/ml polyadenylic acid, 20% 20x standard saline citrate (SSC), 5% 0.5M 
sodium phosphate pH 7.0, 1% 0. IM sodium pyrophosphate and 10% dextran sulphate made 
up to 50 ml with DEPC-treated water]. After adding DTT 4:100 mixture was vortexed 
thoroughly. 2 0 0 pl of this mix was applied to each slide.
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For control hybridisation, a 50 folds excess of unlabelled “cold” probe was added to test for 
displacement of the specific signal.
Solution added Control mix Test mix
Hybridisation buffer 2 0 0  pi 2 0 0  pi
IM D T T 8  pi 8 pi
Hot Probe 2  pi 2 pl
Cold Probe 
(5 n g /p l 
stock soln)
16 pi -
Table 7. Hybridisation mixture for in situ hybridisation.
The slides were covered with parafilm. Any air bubbles were removed carefully. Four of 
these slides were placed carefully in a petri dish. A piece of tissue paper soaked in 4xSSC 
was placed carefully in one side in the petri dish to maintain humidity. The slides were 
incubated over night at 42®C.
The next day slides were transferred into glass troughs containing 250ml IxSSC. The 
parafilm cover slips were gently removed. The slides were then washed in IxSSC at 60® C 
for 30 mins. with constant agitation. Following this, the slides were briefly washed at RT 
inlxSSC and then 0. IxSSC and then dehydrated through 70%, 95%and then in absolute 
alcohol, all at RT. Slides were then allowed to air dry.
The sections were exposed to autoradiographic film (Biomax MR film, Kodak) at room 
temperature for a week to five weeks, depending on the probe used and the efficiency of 
their tailing. The films were developed using a Kodak Hyperprocessor according to the 
manufacturer’s instructions.
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2.3.2. Data analysis
MCID image analysis system was used for quantification of lEG expression. Relative 
optical density (ROD) measurements were taken from duplicate sections from each animal. 
For each probe, individual one-way ANOVA was carried out for each discrete brain region 
followed by LSD Post hoc analysis to determine statistical significance of any dmg induced 
changes in lEG expression.
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2.4. Results
2.4.1. Results of in situ hybridisation of immediate early gene 
expression after acute treatment with antipsychotic drug 
treatment.
Effect of haloperidol and Y931 on zif 268 mRNA expression
Haloperidol (Img/kg i.p.) and Y931 (10mg./kg. i.p.) increased zif268 mRNA expression in 
the most areas of the brain examined. Haloperidol produced significant increases in zif 268 
mRNA expression levels in most of the regions of the brain measured, with the exception of 
the accumbens shell, and the motor cortex layer 1 (M lLI), layer 2 (M2L1). The most 
marked increases occurred in tlie dorsolateral caudate putamen and the ventromedial caudate 
putamen where increases in zif 268 mRNA expressions level were 196 % and 172% 
respectively compared to vehicle controls.
In contrast, Y931 produced a more restricted pattern of change in zif 268 mRNA expression. 
However, as with haloperidol there was a pattern of change in the caudate putamen and the 
core of the accumbens where the z if268 mRNA expression level was significantly high.
Unlike haloperidol, Y931 failed to induce increases in zif 268 expression in the motor cortex 
(Table 8 page-72; Fig: 4 - 8 , page: 75 -78).
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Effect of haloperidol and Y931 on c-fos mRNA expression
The effect of acute treatment of haloperidol (Img/kg i.p.) and Y931 (10 mg/kg) on c-fos 
mRNA expression are shown in the Table 9 and Fig (4 -  8 ), The acute administration of 
haloperidol produced a significant increase in the c-fos mRNA expression in regions of 
the rat brain measured with exception of motor cortex-1 , the accumbens shell and core 
and retrosplenial cortex layer-1. As with the zif 268 mRNA expression level, the highest 
increases in c-fos mRNA expressions were in caudate putamen, both ventral and dorsal 
caudate putamen. But in contrast to zif-268 mRNA expression, the accumbens core did 
not show significant increase in c-fos expression level after treatment with either of the 
drugs. In some other cortical regions, haloperidol significantly increased c-fos mRNA 
expression, such as retrosplenial cortex (RSA L2) and the somatosensory cortex (S lL l 
and SI L2).
The most significant increase of c-fos mRNA expression occurred following the acute 
tieatment of Y931 in the dorsolateral caudate putamen. In contrast to the zif268 expression 
level, the ventral region of caudate putamen did not show a significant increase in c-fos 
expression levels after treatment with Y931. However there was a similar percentage 
increase (=60%) in both cases. But the expression level of c-fos mRNA, after treatment with 
Y931 was significantly higher than that of haloperidol in the dorsolateral caudate putamen, 
as well as in comparison to that of the contiols (Table -9, page-74 and fig: 4-8, page: 75 - 
78).
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Zif-268mRNA expression Inmotor cortex
150
« 100
I Veh/hal 
lVeh/Y931
M1I1 M1L1 M1L2 M1L2
c^fos mRNA expression in
motor cortex
200
100 - a
M2L1 M2L1 M2L2 M2L2
Fig.4. Effect of acute haloperidol (1 mg/kg i.p.) and Y931 (lOmg / kg i.p.) on zif268 and c-fos 
mRNA expression in the motor cortex, 45min after antipsychotic drug administration. Data 
represent mean % control ± SEM (n=8) analysed using one way ANOVA followed by LSD Post 
hoc analysis *?<0.05 compared to respective vehicle. # P< 0.05 compared to haloperidol.
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zif-268 mRNA expression in
cingulate cortex 200n
150
■3 100
iVeh/ 
lVeh/Yg31
o  100-
c-fos mRNA expression in
cingulate cortex
*
c g i  Cg1 Cg2 Cg2
Cg1 Cg1
Fig.5. Effect of acute treatment of haloperidol (1 mg/kg i.p.) and Y931 (10 mg/kg i.p.) on zif268 
and c-fos mRNA expression in the cingulate motor cortex (Cg) areas after 45min. of 
antipsychotic drug administration. Data represent mean % control ± SEM (n=8) analysed using 
one way ANOVA followed by LSD Post hoc analysis *P<0.05 compared to respective vehicle.
c-fosmRNA expression in 
caudate putamen
300-1
Zf-268 mRNA expression in caudate putamen
2  200
Veh/hal y 00 
lVeh/Y931 600
■5 500
■£ 400
DLCPu DLCPu VMCPu VMCPu
Fig.6. Effect of acute treatment of haloperidol (Img/kg i.p.) and Y931 (10 mg/kg i.p.) on zif268 
and c-fos mRNA expression in dorsolateral and ventro-lateral caudate putamen (DLCPu and 
VMCPu) after 45min. of antipsychotic drug administration. Data represent mean % control ± 
SEM (n=8) analysed using one way ANOVA followed by LSD Post hoc analysis *P<0.05 
compared to respective vehicle. # P< 0.05 compared to haloperidol.
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zf-268 mRNA expression inaccumbens shell and core
200-1
100-
AcbSh AcbSh AcbC AcbC
Veh/hal
lVeh/Y931
C-fosmRNA expression in
accumbens shell and core
200-1
100 L
AcbSh AcbSh AcbC AcbC
Fig.7. Effect of acute treatment of haloperidol (Img/kg i.p.) and Y931 (10 mg/kg i.p.), on zif268 
and c-fos mRNA expression in the accumbens shell (AcbSh) and core (AcbC), after 45min. of 
antipsychotic drug administration. Data represent mean % control ± SEM (n=8) analysed using 
one way ANOVA followed by LSD Post hoc analysis # P< 0.05 compared to haloperidol.
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BV ehicle
Haloperidol
Y931
Cingulate cortex
Motor cortex 
2+1 
[I, II, III,
Accumbens 
Shell
Con
Dorsal
Striatum
Ventral
V ehicle
Haloperidol
. . y
Y 93I
Fig.8. In situ hybridisation autoradiographic localization of Zif-268 (A) and c-fos (B) mRNA 
expression in different areas rat brain at Level-1. Rats were treated with vehicle (0. 5%HPMC), 
haloperidol (Img/kg), and Y931 (10 mg/kg). Brains were collected after decapitation and frozen at - 
-42  ^after 45 mins APD treatment.
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In the next study of lEG expression, zif-268 and c-fos mRNA were tested after 
administration of haloperidol (Img / kg), olanzapine (10 mg / kg) and Y931 (lOmg/kg) to 
compare the lEG expression level of Y931 to that of olanzapine. The relevant dose level of 
olanzapine for the rats were selected based on its clinical dose equivalence to haloperidol. 
Results were obtained for zif 268 mRNA expression. (Table 10, page-80).
In this study, haloperidol failed to increase zif 268 mRNA expression level in the motor 
cortex and other brain regions (cingulate cortex and striatum). Similarly, Y931- induced 
changes in zif-268 mRNA expression levels were less apparent in the caudate putamen 
and were not significant.
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To investigate the results obtained in the motor cortex in more detail as the results were 
very different than our first lEG experiment, the autoradiogiaphs were re-examined with 
readings being taken with a higher level of anatomical resolution. This did not reveal any 
haloperidol-induced changes. However both olanzapine and Y931 significantly reduced 
zif 268 mRNA expression level in most of the motor cortex (Table 11, page: 82)
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A similai’ pattern of changes was detected with c-fos as with zif268 in this study, as 
shown in the next Table 12 (page-84). Thus haloperidol produced less marked changes on 
c-fos mRNA expression than in the previous study, although there were still significant 
increases on expression level in the caudate putamen. Olanzapine and Y931 also induced 
significantly higher c-fos mRNA expression in this region, except VMCPu, where it was 
not significant with olanzapine.
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2.4.2. Results of in situ hybridisation for marker genes of motor 
circuits after acute treatment with antipsychotic drugs.
Effects of haloperidol and Y931 on GAD67 mRNA expression 
level.
The expression level of GAD67 mRNA 45 minutes after acute treatment with haloperidol 
and Y931 is shown in the Table 13. The two parts of the substantia nigra regions were 
investigated, the areas where the GAD 67 mRNA was expressed. The expression levels 
were not significantly affected after treatment with haloperidol or Y931in comparison to 
vehicle controls in any of the areas of interest.
Brain region Vehicle Haloperidol %Vehicle Y931 % Vehicle
ROD ROD Control ROD Control
SNL 0 .115±0.009 0.122±0.008 106.5±6.9 0.1264=0.014 1104=12.2
SNR 0.053±0.009 0.624=0.009 U7.2±16.7 0.0634=0.007 117.24=13.1
Table 13. Effect of acute haloperidol (Img/kg) and Y931 (10 mg/Kg) on GAD67 mRNA 
expression in substantia nigra lateral (SNL) and substantia nigra reticulata (SNR), 45 
mins. after APD treatment. Data shown as mean optical density (ROD) ± SEM and as 
mean percentage of vehicle control (control "= 100 %, n = 8  per group). Data analysed by 
one way ANOVA followed by LSD multiple range tests where appropriate.
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Effect of haloperidol and Y931 on glucose regulating protein76 
(grp75) expression levels after acute treatment.
Effect of acute treatment of haloperidol and Y931 on glucose regulating protein-75 
(grp75) is shown in the Table 14. The two areas of the rat brain that expressed substantial 
number of gi'p75 containing nuclei were the substantia nigra pars compacta (SNCD) and 
the subthalamic nucleus (STN). However, the mRNA expression levels were not 
significantly affected by haloperidol or Y931 treatment when compared to the vehicle 
controls.
Brain region Vehicle Haloperidol % Vehicle Y931 % Vehicle
ROD ROD Control ROD Control
SNCD 0.095±0.003 0.1044=0.003 110.14=3.7 0.0924=0.005 97.74:6.0
STN 0.0984=0.016 0.1024=0.007 103.44:7.3 0.097=t0.007 99.04:6.8
Table 14. Effect of Haloperidol (Img/kg) and Y931 (10 mg/kg) on grp75 mRNA 
expression in the substantia nigra compacta (SNCD) and subthalamic nucleus (STN), 45 
mins. after APD treatment. Data shown as mean optical density (ROD) ± SEM and mean 
percentage of vehicle control (control = 100, n = 8  per group). Data analysed by one way 
ANOVA followed by LSD multiple range tests where appropriate.
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Effect of haloperidol and Y931 on NOS expression level after 
acute treatment.
In this experiment the levels of NOS mRNA were measured only in subthalamic nucleus 
(STN) of rat the brain. However the expression level of NOS mRNAwas not changed by 
haloperidol or Y931 in this nucleus (Table 15).
Brain Vehicle Haloperidol % Vehicle Y931 % Vehicle
region ROD ROD control ROD control
STN 0.1716 ±0.017 0.166±0.012 96,68±6.8 0.173+0.0005 100.9T0.32
Table 15. Effect of acute haloperidol (Img/kg) and Y931 (10 mg/kg) on NOS mRNA 
induction in the subthalamic nucleus (STN), 45 mins. after APD treatment. Data shown 
as mean optical density (ROD) ± and as mean percentage of vehicle control (control = 
100%, n == 8  per group). Data analysed by one way ANOVA followed by LSD multiple 
range tests where appropriate.
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2.4.3. Summary of the results of the patterns of gene expression induced 
by acute treatment of Y931 and haloperidol, after 45 minutes of 
antipsychotic drug treatment.
In the first experiment, treatment with haloperidol (Img/kg) and Y931 (10 mg/kg), 
produced wide spread changes in zif268 and c-fos mRNA expression. In contrast, Y931 
produced a more restricted pattern of change in lEG expression level.
Haloperidol induced zif-268 mRNA expression significantly in the cingulate cortex, 
motor cortex M1L2, striatum and nucleus accumbens core but there was no significant 
change in the accumbens shell and motor cortex M lL l and M2. Most marked increases 
occurred in the dorsolateral and ventrolateral caudate putamen, where increases in zif 268 
mRNA levels after haloperidol were to 196% and 172% of controls respectively, 
compared to vehicle controls.
In contrast Y931 produced more restricted pattern of lEG expression. After treatment 
with Y931, zif268 mRNA expression levels were confined to the caudate putamen (both 
dorso-lateral and ventro-lateral) and the nucleus accumbens core. These changes were of 
a similar in magnitude to those produced by haloperidol. Y931 did not cause an increase 
of zif 268 mRNA expression in the motor cortex that was observed after treatment with 
haloperidol.
The acute administration of haloperidol produced a substantial increase in the c-fos 
mRNA expression in all regions of the rat brain, with exception of motor cortex M l and 
the accumbens shell and core. The highest increases in c-fos mRNA expression were in 
caudate putamen, both ventral and dorsal region. In contrast to zif 268 mRNA expression 
level, the accumbens shell and core did not show significant increases in c-fos mRNA 
expression level.
The most significant increase of c-fos mRNA expression occurred following the acute 
treatment of Y931 was in the dorsolateral caudate putamen. In contrast to the zif268 
mRNA expression level, the ventral region of caudate putamen did not show a significant
increase in c-fos mRNA expression by Y931. However, there were a similar percentage 
of increases (=60%) in both cases. In contrast to zif 268 mRNA expression, c-fos mRNA 
was not significantly expressed after treatment with Y931in the accumbens core. And 
after treatment with Y931, c-fos expression level was considerably lower than 
haloperidol in the accumbens shell.
The most marked increases in the zif268 and c-fos mRNA levels occurred in the 
dorsolateral caudate putamen after haloperidol treatment was 196% and 430% of controls 
respectively. But after treatment with Y931 the expression level of zif 268 and c-fos 
mRNA in this area was 231% and 670% of control respectively.
In the second experiment of lEG expression after treatment with haloperidol (Img/kg), 
olanzapine (lOmg/kg) and Y931 (lOmg/kg as before), the altered expression level of zif 
268 and c-fos mRNA was not the same in motor cortex as in the first experiment. The 
expression level of zif268 was significantly lower in all motor cortex areas after 
treatment with Y931 and olanzapine. The expression level of zif 268 and c-fos mRNA 
appeared to be lower with Y931 than the olanzapine, but was not significant.
One of the reason for repeating the experiment was to determine the reproducibility of the 
potentially interesting finding that haloperidol, but not Y931 induce increased lEG 
expression in most o f the motor cortex. For this purpose, we used a more refined image 
analysis protocol to study lEG expression in individual define layers of the motor cortex. 
The results from the two studies were still different and we cannot find any obvious 
reason for this. However, in other areas (caudate putamen, dorsal and ventral) the results 
were broadly similar in the two studies (but smaller increases), for both zif268 and c-fos 
mRNA expression.
Haloperidol increased the expression of zif268 and c-fos mRNA dramatically, as 
expected. This is the first report that showed that atypical antipsychotic drug olanzapine 
also increases c-fos in the striatum. The increase in expression level of zif268 was not 
significant in these areas in this experiment. But the overall results are consistent with the
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concept that striatal c-fos and zif268 are regulated in parallel. Treatment with Y931 
produced a greater induction of striatal c-fos and zif268 mRNA expression level than 
treatment with haloperidol. This may reflect the high affinity of Y931for D% receptors.
The other interesting point was that the treatment with Y931 produced more marked 
increases in c-fos mRNA expression in the dorsolateral caudate putamen. This effect was 
greater than that which occurred after treatment with haloperidol (670% of control with 
Y931; 430% of control with haloperidol in experiment-1).
Thus the result o f the lEG induction indicates that Y931 modulates striadopallidal 
neurons with its neurochemical activity.
This is also indicative that Y931 should cause some EPS.
Neither haloperidol nor Y931 altered the expression level of GAD 67, grp-75 or NOS 
mRNA levels in the discrete region of the basal ganglia after 45mins antipsychotic drug 
treatment. It was expected that, at least after haloperidol treatment, activity of these 
nuclei would be altered. Hence these genes are probably not good markers of regional 
activity, at least, at the time point studied here.
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Chapter 3: Effect of serotonin antagonists, S-HTzc/zb 
and 5-HT2C on haloperidol induced catalepsy.
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3.1. Introduction and Aim.
In the current model of basal ganglia circuitry, blockade of dopamine receptors can result 
in increased activity of neurons tliat project from striatum to the external globus pallidus. 
This may lead to dis-inhibition of the subthalamic nucleus resulting in the increased 
excitation of the circuits to the internal pallidum. This may cause increased inhibition of 
thalamo-cortical neurons. Normally there is a balance between dopaminergic and 
cholinergic tone in the striatum. When this balance is disrupted causing dopaminergic 
hyperactivity and thalamo-cortical inhibition, Parkinson like symptoms [Extrapyramidal 
Side Effects (EPS)] may be caused (DeLong, 1990).
Antipsychotics (i.e. the so- called major tranquilisers) are used in the treatment of 
schizophrenia. In 1950s these agents were adopted for the treatment of schizophrenia 
because of their selective antipsychotic efficacy and rapidly replaced the previously used 
medications that were merely sedating. A number of studies compared the effects of these 
first generation antipsychotic drugs with those of general sedatives such as barbiturates. 
These studies had shown that these compounds have a specific antipsychotic action that 
are not possessed by general sedatives (Klein and Davis, 1969). Typical antipsychotic 
drugs such as haloperidol result in catalepsy in experimental animals, which is an 
indication of the drug’s EPS liability. A similar effect is also expressed, although to a 
lesser degree, by the atypical antipsychotic drugs, except clozapine. Ddifferent brain 
regions mediate catalepsy and DA agonist-induced locomotor hyperactivity and 
stereotypy. The potency of atypical antipsychotic drugs when compared to the potencies 
of the typical antipsychotics to influence these behaviors may indicate an anatomic 
specificity of action that confers a favorable spectrum of activity upon the atypical drugs 
(Kinon and Lieberman, 1996).
Antipsychotic drug induced catalepsy is well known to be due to the blockade of 
dopamine neuro-transmission via D2 receptors, as catalepsy in rodents or EPS in primates 
/ human is presumed to reflect the activity of the nigrostriatal dopamine (DA) pathway
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(Calderon et al., 1988; Costall and Naylor, 1974; Sanberg et al., 1980). The atypical 
antipsychotic drugs have high affinity for serotonin receptors, 5HT2 subgroups, as well as 
dopamine D2 receptors. But the affinity for D2 receptors of atypical drugs is usually less 
than for the typical antipsychotic drugs. Biochemical studies have shown that there are 
reciprocal interactions between DA and 5 HT2 systems within the CNS and the cataleptic 
effect of antipsychotic drugs depend on the balance between the dopaminergic and 
serotonergic system (Balsara et al., 1979). There are convincing reports to suggest that 
serotoninergic activity of atypical antipsychotic drugs reduce neuroleptic-induced 
catalepsy (Balsara et al., 1979; Meltzer, 1989, 1996; Poyurovsky and Weizman, 1997; 
Reavill et.al. 1999). Serotonergic neurons are thought to normally inhibit dopaminergic 
neurotransmission in the CNS, as a reduction of serotonergic activity increases the 
functional activity of nigrostriatal DA neurons. The striatum receives serotonergic input 
from the raphe nuclei, as do the dopaminergic cell bodies in the substantia nigra (SN). 
Alterations in serotonergic neurotransmission are also known to alter DA-mediated motor 
behaviours. Chewing and biting, licking or grooming with tongue etc., are examples of 
motor activity associated with 5HT in adult animals. Cataleptogenic effect of neuroleptics 
apparently depends on the balance between the two systems (Balsara et a l, 1979). The 
serotonin receptors 5HT2a and 5HT2c have been implicated in hyperactivity and 
stereotypy, orofacial dyskinesia, etc. in conjunction with dopamine (Neal-Beliveau et a l, 
1993; Bberle-Wang et a l ,  1996).
Atypical antipsychotics have high affinity for serotonin receptors, especially the 5HT2a and 
5 HT2C receptors. When serotonergic activity is blocked, dopamine release increases and 
balances out the dopamine blockade effect at presynaptic receptor site, resulting in 
putatively less or no EPS (Fox et a l, 1998). It had been reported that selective 5HT2c and 
5HT2C/2B antagonists significantly reverse haloperidol induced catalepsy, whereas 5HT2a 
and 5 HT2B receptor respectively did not reverse haloperidol-induced catalepsy (Di 
Giovanni et a l, 1999; Di Matteo et a l, 1999),thus suggesting, that the activity of 5HT2c 
receptors is most probably important in protection against extrapyramidal side effects.
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Furthermore, there is evidence, indicating 5-HT2c receptor antagonist, SB-206553 when 
injected into the substantia nigia pars reticulata produces an antiparkinsonian effect. This 
may indicate that 5-HT2c receptor antagonism may produce a favourable result in the 
situation of motor disturbance (Eberle-Wang et. a l ,  1996; Fox et. a l, 1998). However, 
few drugs have differential affinity for 5HT2b and 5HT2c receptors, and the role of 5HT2b 
and 5HT2C receptors in reducing EPS has not been explored in veiy many studies.
Y931 has high affinity for dopamine D2 receptors, showing high D2 receptor blockade in 
the striatum. It also has very high affinity for 5 HT2 receptors, specifically 5HT2c 
receptors. The evidence suggests that Y-931 has very little tendency to produce EPS. 
Because of this, our aim for this part of the experiment is to look into the effects of 
5 HT2C receptor antagonists on haloperidol induced catalepsy. If the 5HT2c receptor 
antagonists reduce the haloperidol-induced catalepsy and produce a luRNA expression 
profile like that of Y931, that may explain the method of activity of Y931 in the 
reduction of EPS.
We have also measured the different gene expression levels of specific marker genes of 
different areas of basal ganglia on the brain tissues of these rats to map the gene 
expression three hours after treatment with the drugs. This might help us to find out any 
change in the mRNA expression level in the presence of 5 HT2 antagonists after treatment 
with haloperidol, Y931 and olanzapine. The pharmacological profile of Y931 is very 
similar to that of the atypical antipsychotic drug, olanzapine. So we have decided to 
compare the gene expression level of Y931 with this atypical antipsychotic drug as well 
as the typical drug haloperidol. Comparison of these results would help us to understand 
the mechanism of activity of Y931 and to find out if  Y931 is an atypical drug with lower 
EPS.
The catalepsy tests were used to check EPS liability of antipsychotic drugs, as these tests 
have high predictive accuracy (Sanberg et a l, 1988; Wadenberg and Hicks, 1999).
Thus two methods were used for this part of the study:
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a) Animal behavioral Test (measurement of catalepsy).
b) In situ hybridisation (measurement of site specific gene expression level which could 
give indication of metabolic activity).
3.2. Materials and methods
Name of the drugs Source Dosage
1. Haloperidol RBI 1 mg / kg
2. Olanzapine Welfide Corporation 10 m g / k g
3. Y931 Welfide Corporation 10 m g / k g
4 SB 200646 (SB-1) 
5HT2C/2B
TOCRIS 10 m g / k g
5. SB 242084 (SB-2) 
5HT2C
SIGMA - RBI 10 m g / k g
Table 16. Drugs used for animal behavioral experiment. Olanzapine (Moor et al., 1992; 
Beasley et al. 1996) an atypical antipsychotic di'ugs in use. SB 200646 is a selective 5- 
HT2c/2B-receptor antagonist with pki value 6.9 for serotonin 2c receptors and with pi 
value 7.5 for serotonin 2b receptors. SB200646 has 50-fold selectivity for 5-HT2c and 5- 
HT2B over 5 -HT2A receptors (Kennett et al., 1994). SB 242084, a selective 5-HT2c 
receptor antagonist with pki value 9.0 for serotonin 2c receptors. It has 100 and 158-fold 
selectivity over the 5 -HT2B and 5-HT2A receptors subtypes respectively. Thus SB242084 
is a useful tool to evaluate the effect of selective blockade of 5-HT2c receptors. (Matteo et 
al., 1999). The relevant dose levels of olanzapine for the rats were selected based on its 
clinical dose equivalence to haloperidol.
Forty male hooded Long Evans rats (225g -290g) were used for this experiment. The rats 
were housed in-gioup of 5 in each cage under a 12 hours light and dark cycle with free 
access to food and water. The animals were allowed one week of adaptation to
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laboratory conditions before being used in experiment. The animals were randomly 
allocated to six groups:
Group A. Vehicle / Vehicle
Group B Vehicle / Haloperidol
Group C SBl. / Haloperidol
Group D SB2 / Haloperidol
Group E Vehicle / Olanzapine
Group F Vehicle/Y931
In each case vehicle was 0,5% HPMC as before. Because of the number of animals and 
several stages of experiment, the study was conducted in two days.
3.2.1.Animal behavioural Test:
Catalepsy Test
The classic tests for dopamine (DA) antagonist activity is to measure the ability of a drug 
to induce a state of catalepsy in rodents (Costall and Naylor, 1974). Functional responces 
elicited by DA agonists include activation of locomotor activity, steriotypy and rotation 
in rats with unilateral 6-oHD A-induced lesions o f the nigrostriatal pathway.
Catalepsy is a phenomenon defined as the long -  term enduiance of an abnormal posture 
by the experimental anima after antipsychotic drug treatment 1, without being able to 
correct it. When a normal animal is placed in an unusual posture, it will change its 
position within seconds. In contrast, cataleptic animals will maintain this posture for
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several minutes or longer, dependent upon the degree of catalepsy. The catalepsy tests 
have been widely used as a preclinical test to predict and motor side-effect liability of 
antipsychotic drugs, i.e., EPS liability of new antipsychotic drugs. These tests have high 
predictive accuracy (Sanberg et al., 1988; Wadenberg and Hicks, 1999) to measure EPS. 
Catalepsy is observed with typical and atypical antipsychotic drug treatment, when doses 
used produce D2 receptor occupancy >85%.
A typical catalepsy test consists of placing an animal into an unusual posture and 
recording the time taken to correct this position (i.e., the four paws of the experimental 
rat should be extended and abducted, Morelli and Chiara, 1985). This time is regarded as 
an index of the intensity or degree of the catalepsy. A variety of apparatus can be used - 
including wire grids, single bar, parallel bars, platforms or pegs to situate the animals in 
an unusual position. Whilst catalepsy is a robust behaviour, its absolute intensity may be 
affected by minor alteration in various experimental and enviromnental parameters such 
as repeated testing and handling (Sanberg et al., 1988; Di Chiara et a l, 1979; Ôgren etal, 
1986).
Two methods of catalepsy testing were employed in the present studies. These are 
described below.
A, Block Test
The rats were positioned with their forelimbs placed on top of a 10 cm high metal block 
and the hind limbs on the bench. The length of time the rats maintained this position, 
without a deliberate move to step down, was recorded by stop - watch. The rats were 
judged to be cataleptic if  they maintained their position for >30 sec. or more on the block 
without trying to move from the set position. Catalepsy was measured up to a maximmn 
of 2.5 mins. This procedure was conducted both 60 min. and 120 min. following 
antipsychotic drug administration.
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The tests were measured ‘Blind’ with the person recording the activity unaware of the 
treatment the rat had received in a ‘quiet’ room.
180 min. post antipsychotic drug treatment, the rats were sacrificed by decapitation 
(Kalkman, et.al. 1998)
The observed data for time spent on the block were plotted in giaph form as means 
±SEM after one way ANOVA was carried out.
B. Grid Test
A vertical (angle, 90^) 10 cm. high grid, made with a wire mesh screen, was placed on the 
bench. The animals were placed on the grid, with all foui’ paws on the wire mesh in a 
‘frog’ posture. The use of such an unnatural posture is essential for the specificity of this 
test for catalepsy (Morelli and Chiara, 1985). The time rat remained in the same position 
without moving any of their paws, was then measured for a maximum of one minute. The 
time at which the animal made the first paw movements were measured. An animal was 
considered cataleptic, when the animal stayed immobile on the same position for >30 sec.
The tests were measured ‘Blind’ as before.
All the observed data for the time rats spent on the grid were then plotted as means 
±SEM after one way ANOYA was carried out.
Animals were pretreated with either the 5HT2C/2B receptor antagonist SB200646 or the 
5HT2C receptor antagonist SB242084 and their ability to modify haloperidol-induced 
catalepsy was examined. Parallel groups, comprised a Y931 gioup and an olanzapine 
group. The experimental protocol is summarised in table 17 (page-100).
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“ 15 mins. 
(pretreatment)
T = 0 +60 mins 
Test -1
+ 120 mins 
Test - 2
+180mins
animals
sacrificed
Pretreatment Treatment 1. Block Test 1. BlockTest
( i p ) ( i p ) Animals wereVehicle Vehicle 2. Grid Test 2. Grid Test sacrificed
(0.5%HPMC) (0.5%HPMC) or
or Haloperidol
SBl (1 mg/kg) or
(lOmg/kg) Olanzapine
or (lOmg/kg) or
SB2 Y931
(10 mg/kg) (10 mg/kg)
Table 17. Outline of the experiment on animal behaviour upon haloperidol-induced 
catalepsy and effect of SBl (5 HT2C+2C antagonist) and SB2 (5 HTac antagonist).
After animals were sacrificed, the brains were collected in the usual manner as before, for 
in situ hybridisation analysis (4.2.).
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Results of block tests and grid tests*.
It is evident from the table 18 and from Fig. 9 and 10 that at 60 minutes post APD, there 
was no emergence of catalepsy, after the haloperidol treatment. Olanzapine and Y931 
both appear cataleptic according to the block test at the later time, but the behaviour of 
these animals were not entirely consistent with cataleptic behaviour. The sedative effects 
(most probably due to the blockage of histamine receptors) by olanzapine and Y-931 
made it difficult to judge catalepsy in these animals. Similar physical conditions in the 
experimental animals treated with antipsychotic drug, were also described by other 
authors (Costall and Naylor, 1975). There was a tendency for SB 200646 to reduce the 
cataleptic effect of haloperidol, as assessed by the block test, at 1 2 0  min, but this was not 
significant. There was no such effect by any of the 5 HT2c antagonists with tlie grid test.
Treatment Block Test Grid Test
Test-1 No of Test-2 No of Test-1 N o o f Test-2 N o o f
Mean animals Mean animals Mean animals Mean time animals
Time
(Sec.)
calalepl 
in each 
gp.
Time
(Sec.)
catalept 
in each 
gp-
Time
(Sec.)
catalept 
in each 
gp.
(Sec.) catalept 
in each 
gp-
V eh / Veh 1.3±0.29 0 /6 7.0+2.0 0 /6 3.8+2.7 0 /6 12.2+3.8 1 /6
V eh /H al 7.5±4.2 1 /8 42.0+25.2 3 /8 7.6+3.5 0 /8 38.5+8.5 4 /8
S B l/H a l 6.9±4.3 1 /7 16.0+2.8 1 /7 10.0+3.0 0 /7 27.4+7.0 3 /7
S B 2 /H al 17.0±7.5 1 /7 37.7+8.8 5 /7 17.3+6.7 1 /7 28.2+8.5 2 /7
Veh/Olanz 14.6+5.4 1 /6 130.8+49 3/6 5.5+3.2 0 /6 19.7+8.4 2 /6
Veli/Y931 27.7+14.7 1 /6 48,3+14.7 4 /6 5.8+2.4 0 /6 14.0+6.8 1 /6
Table 18. Effect of treatment on groups of rats with haloperidol (Img/kg), haloperidol and 
SBl (lOmg/kg, i.p.), haloperidol and SB2 (10 mg/kg, i.p.), olanzapine (lOmg/kg, i.p.) or 
Y931 (lOmg/kg, i.p.) on the cataleptic behaviour of rats. Catalepsy was assessed as amount 
of time rats spent on the block or grid for >30 sec. Results are expressed as the mean ± SEM 
after one way ANOVA with each treatment.
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Effects of haloperidol and haloperidol +SB200646 (SB 1) or haloperidol 
+SB242084 (SB2) in comparison to the effect of olanzapine and Y931
2001 
1 8 0 - 
1 6 0 - 
1 4 0 - 
120 -  
100 
8 0 - 
6 0 - 
40 
20-1 
n
Catalepsy Block test: 60mins. 
Post APD CZ3 Veh/Veh 
l a s  Veh/hal 
œaaaSBi/hal ^  
H lS B 2 /h a l  o 
Veh/olanzS
mui Veh/Y931.E
Catalepsy Grid test: GOmins. 
Post APD
2 0 0 n
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140-
120 -
100
BOH
60
40-
20
Fig.9. Catalepsy Block Test and Grid Test: Effects of haloperidol (1 mg/kg i.p.) and haloperidol 
+SB200646 (SB 1, 10 mg/kg, i.p.) or haloperidol + SB242084 (SB2, 10 mg/kg, i.p.) in 
comparison to the effect of olanzapine (10 mg/kg) and Y931 (10 mg/kg) 60 mins after drug 
treatment.
Catalepsy was assessed as amount of time rats spent on the block or grid for >30 sec. Results are 
expressed as the mean ± SEM time spent by each group of rats after one way ANOVA with each 
treatment. The number of animals in each treatment group are 6-8 as shown in Table 18.
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Catalepsy Block Test: 120 mins 
Post APD
S 140
Ô  100-
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200 - ]  
180- 
160- 
140- 
120 -  
100 
80 
60 
40 
20
Catalepsy grid test:120 mins 
Post APD
■ ■ jn m .
Fig. 10. Catalepsy Block Test and Grid Test; Effects of haloperidol (Img/kg i.p.) and 
haloperidol +SB200646 (SB 1, 10 mg/kg, i.p.) or haloperidol +SB242084 (SB2, 10 
mg/kg, i.p.) in comparison to the effect of olanzapine (10 mg/kg) and Y931 (10 mg/kg) 
1 2 0  mins after drug treatment.
Catalepsy was assessed as amount of time rats spent on the block or grid for >30 sec. 
Results are expressed as the mean ± SEM time spent by each group of rats after one way 
ANOVA with each treatment. The number of animals in each treatment group are 6 -8  as 
shown in Table 18.
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3.2.3. Modified cataiepsy test: Dose related effects of 
haloperidol on catalepsy, using 'BAR TEST'.
Since the results with the catalepsy tests after haloperidol treatment were not totally clear 
in the first experiment, it was decided to repeat the experiment using two doses of 
haloperidol: Img/kg i.p. and 2mg/kg i.p.
The method for the animal behaviour test was changed using bar method, the protocol of 
Reavill et a l, 1999 to increase reproducibility.
• Instead of a 10 cm. Block, a 1 cm. diameter metal bar on a retort stand, raised 10 cm
above bench level was employed. The front paws were gently placed on the
horizontal metal bar. It is important that four paws be well extended.
• The measurement of catalepsy:
• If the rats climbed down from the bar straight away, they were put back on the bar
again. This ‘training’ element was done for a maximum of three times, as it had been 
reported that catalepsy measures are more reliable if  the animals experience the test 
repeatedly (Reavill et all999).
#
Tests were conducted at 30mins, 60mins, 90 mins, and 180 mins. The observed data 
for the time rats spent on the bar at these various time points, were then plotted as 
means ± SEM after one way ANOVA was carried out.
The rat was deemed cataleptic if it stayed on the bar for 30 sec or longer. If the rats 
were cataleptic they were given a score 1, if  not they scored 0. If it stayed on for 30 
sec., it was kept on the bar for maximum of 2  mins and then taken off the bar, unless 
it got down by itself.
103
Materials and Methods
Drugs and other materials were from the same sources as before and were prepared same 
way as before.
Twelve male hooded Long Evans rats (225g - 300g) were used for this experiment as= = = = =
into four groups:
A. V eh-V ehicle  (0.5% flPMC) 1ml /kg
A. Hal. 1 - Haloperidol lii^g / kg
B. H A L . 2 - Haloperidol 2 m g / k g
C Y 931-Y 931 10 m g / k g
The observed data for time spent on the bar were plotted in graph form as means ±SEM 
after one way ANOVA was carried out.
104
3.2.4.Results
In this experiment, haloperidol induced clear catalepsy at the 2mg/kg dose at all time 
points. The emergence of catalepsy in rats treated with Img/kg haloperidol was not 
apparent until thiee hours after drug treatment. In the two animals that received Y931, 
catalepsy was again difficult to assess because of the ‘sedatory’ effects of Y931 (Table- 
19, fig: 11, page: 105-106).
Treatment
BAR TEST
Vehicle Test -1 T est- 2 Test -  3 Test -  4
(30mins after (60 mins after (90 mins. after (ISOmins. after
APD)mean ±  SEM APD) mean+SEM APD) mean+SEM APD) mean+ SEM
Vehicle
(sec.) (sec.) (sec.) (sec.)
\\~2 1 + 0 .3 5 2 .5 +  1.8 6 .5 +  6.5 1 3 .5+ 1 .06
Haloperidol
Im g /k g
n=4
0 + 0 4 .2 4 + 1 .9 11.0 + 2.8 79.5+31.7
Haloperidol
2mg / kg 
n=4
12.8 + 4.5 71.75+ 25.0 96.25 +20.6 120 + 0
Y931
(10 m g /k g )  
n=2
0 + 0 13.5+7.4 75.0 + 37.5 70.0+35.46
Table 19. Table showing the time animals stayed on the bar tieatment with Img / kg and 
2mg / k g , i.p. of haloperidol or 10 ng/kg Y931. Catalepsy was assessed as amount of time 
rats spent on the bar for >30 sec. Results are expressed as the mean ± SEM time spent by 
each group of rats after one way ANOVA with each treatment.
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Effect of different dosage of haloperidol on catalepsy at 90 mins. after 
APD administration
Measurement of catalepsy 
at 90 mins.
Time on bar 
(sec.)
120
90
6 0 -
30-
No of cataieptic 
animals
Measurement of catalepsy 
at 180 mins.
120
mZ3 veh 1 ml / kg
90
CZZD h a ll mg / kg 
■ ■ h a l 2 m g /k g  60
30
No of cataieptic 
animais
Fig.l 1. Catalepsy Bar Test: Effects of haloperidol (Img/kg i.p. and 2 mg/kg i.p.) after 90 
mins and 180 mins of drug treatment. Catalepsy was assessed as amount of time rats spent 
on the bar for >30 sec. Results are expressed as the mean ± SEM time spent by each 
group of rats after one way ANOVA with each treatment.
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3.3. Animal behavioural Test (Repeat):
Based upon the results of the previous experiment it was decided to repeat the experiment 
with serotonin 5 HT2c/b antagonist SB200646, to investigate its effect on haloperidol- 
induced catalepsy using haloperidol at a dose of 2  mg/kg.
Materials and methods: 
Drugs used:
1. Haloperidol 2mg /kg
2. Olanzapine 10 mg / kg
3. 5HT2c/2b 1 0  m g / k g  
(SB 200646 = SBl)
Sources of the drugs were as before.
Drugs were prepared as described previously.
Twenty-four male hooded Long Evans rats with a weight range o f . 225 -  300g were used 
for this experiment. The animals were randomly allocated to four treatment groups.
A. Haloperidol
B. Olanzapine
C. SB1+ haloperidol
D SBl + olanzapine
Six animals were allocated in each group.
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0 Time - 1  Time-2 30min 60 90mins. ISOmins.
+ 5 mins. s. mins. APD APD
APD APD
Treatment 1 Treatment 2 Test-1 T est-2 T est-3 T est-4
(i.p.) (i.p.)
Vehicle Haloperidol
(0.5%HPMC) (2 mg/Kg)
or or
SBl Olanzapine
( 1 0  mg/kg) ( 1 0  mg/kg)
Table 2 0 . Outline of the experiment, the effect of SHTib/c antagonist on haloperidol- 
induced catalepsy.
3.3.1 .Results
In this experiment haloperidol (2mg/kg) produced clear catalepsy which was present in all 
animals 90 min post drug treatment. Whilst animals pretreated with the 5HT2B/C receptor 
antagonist SB 200646 appeared to show reduced catalepsy. This was not significant. 
Olanzapine appeared to produce catalepsy in about 50% of animals thiee hours post drug 
treatment, whereas in the group receiving SBl pretreatment, all rats displayed catalepsy 
(Table 21 and Fig-12, page: 109-110).
The observed data for time spent on the bar were plotted in graph form as means ±SEM 
after one way ANOVA was carried out.
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Treatment BAR TEST
Test- 1
(30 mins after APD) 
mean +SEM 
(sec.)
Test- 2
(60 mins after APD) 
mean ±SEM  
(sec.)
Test- 3
(90 mins after APD) 
mean +SEM 
(sec.)
Test- 4
(180 mins after APD) 
mean +SEM  
(sec.)
Veh + hal 
n= 6 8.5 ±  2.0 69.2 + 20.8 108.3+9.0 125.5 + 1.8
SBl+hal
n= 6 12.8 ±9 .5 37 .2+17 .7 87,5 + 8,4 101.7 + 4.7
Veh+ Olan 
n= 6 1.5 ± 0 .8 6 .8 + 2 .4 30.3 + 8.6 54.5 + 7.9
SB1+ Olan 
n= 6 7.2 ± 3 .2 30 .5+18.5 24,5 + 3.7 57.8 + 4.3
Table 21. Table showing the time animals stayed on the bar after pretreatment with SBl 
(10 mg/kg, i.p.) + haloperidol (2 mg/kg, i.p.) or olanzapine (10 mg/ kg). SBl was 
administered 5 mins, before haloperidol or olanzapine. Numbers of animals were six in 
each group. Catalepsy was then measured at 30, 60, 90 and 180 mins. post drug 
administration using the bar test as described before. Catalepsy was assessed as amount 
of time spent on on bar. Catalepsy was defined if the animals stayed >30 sec. on bar. 
After the 180 mins rats were killed by decapitation. Results are expressed as the mean ± 
SEM time spent on the bar.
Method was as per Reavill et. al., 1999.
Influence of SB200646, a 5HT2c/b receptor antagonist on haloperidol 
induced catalepsy after 90 mins. APD
[= 3  Veh/hal 
E H  SB1/hal 
Veh/Olanz 
■ ■SB I/O lanz
Fig. 12. Catalepsy Bar Test; Effects of haloperidol (2mg/kg i.p. and with pre-treatment of 
SBl, lOmg/kg i.p) and olanzapine (10 mg/kg i.p. with pre-treatment of SBl, 10 mg/kg, 
i.p.) after 90 mins of drug treatment. SBl was administered 5 mins. before haloperidol or 
olanzapine. Number of animals were six in each group.
Catalepsy was defined if the animals stayed >30 sec. on bar. After 180 mins rats were 
killed by decapitation. Results are expressed as the mean ± SEM time spent on the bar 
after one way ANOVA with each treatment.
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3.4. Summary of results for animal behavioral experiments
The catalepsy tests are used to check EPS liability, as it is believed that these tests have 
high predictive accuracy for motor function (Wadenberg and Hicks, 1999)
The Img / kg haloperidol dose did not produce reproducible catalepsy in the animals. 
Rats treated with olanzapine and Y931 appealed cataleptic. But the behaviour of these 
animals was not entirely consistent with the cataleptic behaviour. Both olanzapine and 
Y931 have high affinity for Histamine (HI) receptors, which could cause sedation, that 
would make the animal’s movement sluggish and may make them stay on the block or 
grid or bar longer. This could be misread as catalepsy. Since the behaviour of these 
animals appeared sluggish rather than incapable of movement, these results should be 
interpreted with caution.
Serotonin receptor antagonists, specifically the 5HT2 (specifically 5HT2b+2c / 5HT2c) 
receptor antagonists have been proposed to attenuate haloperidol induced catalepsy 
(Meltzer et al., 1995., 1996; Wadenberg and Hicks, 1999; Reavill et al., 1999).
In the combined drug treatment, although I m g / k g  haloperidol dose did not produce 
catalepsy in a significant number of animals, nevertheless, there was a tendency for SB 
200646 (SBl) to reduce the cataleptic effect of haloperidol, as assessed by the block test 
at a later time point (120 mins.). However this was not a significant reduction.
The 2 mg / kg haloperidol dose effectively produced catalepsy in all the animals in the 
group at 90 mins. onwards. Thus confirming the fact acknowledged by other researchers 
(Kapur et a l, 1999, 2000a) that catalepsy or extrapyramidal side effect (EPS) of 
haloperidol and other typical antipsychotic drugs is dose dependent. Our results show 
that, in acute treatment, the dose of haloperidol needed to produce catalepsy would be 
more than Img/kg.
I l l
In second experiment, pretreatment with the SHTib+c antagonist SB 200646, did not 
significantly attenuate haloperidol induced catalepsy. But the result of combined 
treatment of SBl + olanzapine was not as it was expected. Again this could be because of 
the sedative effect of histamine receptor antagonism.
Thus the result of the catalepsy test concluded that the addition of drug SB200646, a 
5HT2C/2B receptor antagonist has minimal influence on the properties of haloperidol to 
induce catalepsy. These results do not support a clear role for SHTac+œ receptors in 
protection against extrapyramidal side effect.
There was not enough time for in situ analysis study on the brain tissues from this study 
which may had given us further information at the mRNA expression level.
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Chapter 4: Comparison of motor circuit marker gene 
mRNA expression levels after treatment with 
haloperidol olanzapine and Y931: Effect of SHTz 
antagonists on haloperidol-induced changes in gene 
expression
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4.1 .Introduction and Aim
According to one of our hypotheses, Y931 acts outside the striatum to subdue the 
activation of the indirect pathway via its significantly high affinity for 5HT2c receptors. 
Y931 may act to suppress EPS at a site downstream of the striatum. 5HT2c receptors 
antagonist property of Y931 may be involved in reducing EPS.
We have pretreated the animals with 5HT2c receptors antagonist 5-HT 2c+2b and 5-HT2c 
before haloperidol treatment. The pretreatment with these serotonin antagonists may 
change result of haloperidol treatment alone and may reflect on the mRNA expression 
level. If this result shows that the mRNA expression level of marker genes at site or sites 
downstream of striatum is similar to that of Y931or olanzapine, that will suggest that 
5 HT2C is involved in the activity of Y931.
There are reports that the expression of certain enzymes and proteins that are involved in 
neuromodulation are regulated in response to altered activity in the indirect pathway. 
These neurochemical components could be used as markers for different regions of basal 
ganglia activity and their influence by neui'oleptic drugs. Some of these molecules are; 
GAD 67, the enzyme responsible for keeping G ABA levels at steady state, which are 
regulated in response to the altered state of the indirect pathway; nitric oxide synthase 
(NOS) which is known to be involved in the neuromodulation in STN; glucose regulating 
protein (grp75), a protein related to hsp70, which is regulated in response to altered 
activity in the indirect pathway in STN; and parvalbumin, a calcium binding- 
neuroprotective protein involved in neuromodulation, a useful marker for GABAergic 
neuronal subtype (Hontanilla et a l, 1997). Thus monitoring the levels of these markers in 
addition to lEGs will help us to establish some characteristics of Y931 that differ from
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haloperidol and olanzapine in its effect on the direct and indirect pathways of the basal 
ganglia.
In this part of the study, changes in gene expression were monitored 3 hours after drug 
administration. Genes such as GAD 67, NOS and grp 75 did not show any change in the 
mRNA expression levels compared to the controls after 45 mins (see Table 13,14 and 15 
in chapter 2, section 2.4.2.). Since these genes are not lEGs, there was a possibility that 
they could be affected by antipsychotic drugs treatment at a later time point.
Because fra-2 is induced more slowly than other lEGs such as c-fos and zif268, fta-2 
mRNA expression levels were also measured at this time point, in this study.
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4.2. In situ hybridisation
4.2.1. Materials and method
All the materials for this part of the experiment are as in the animal behaviour experiment 
in the section 3.2 (page-95). The brain tissue from the animal behaviour experiment in 
section 3.2.1 (page-96) was used for this part of experiment in chapter. The in situ 
hybridisation was conducted as previously described for in situ hybridisation of lEGs 
mRNA expression (see Chapter 2, sections - 2.3, 2.3.1 and 2.3.2, pages-61-65), unless it 
is mentioned otherwise.
Oligonucleotide probes:
Oligonucleotide probe for fra-2 (45 mer) complementary to bases 900-945 of human fra- 
2 mRNA sequence (Kamme et al 1995).
fra-2 (45 mer) 5 ' TAG TTG TTC CCC GCT GCT ACT GCT TCT GCG GTG AGC CTT 
GGAGCA3'
The oligonucleotide probe for parvalbumin was also from GenBank:
Parvalbumin (45 mer) 5' CCC CAG CTC ATC CTC CTC AAT GAA GCC ACT TTT 
GTC TTTGTC CAG 3'
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4.2.2. Results
Effect of haloperidol, haloperidol+S-HTz antagonists, olanzapine and Y-931 
on the Fra-2 mRNA expression levels.
The results of fra-2 expression levels are shown in the table 22 and Fig. 13. The results 
showed that there was no change in fra-2 mRNA expression level in any of the regions 
investigated after treatment with any of the three drugs used. However, in the dorsal 
caudate putamen the effect of treatment approached overall significance (P<0.077) 
producing higher fra-2 mRNA expression levels in compaiison to the controls.
In general, the fra-2 mRNA expression level in presence of Y931 was very similar to that 
o f haloperidol in all areas of motor cortex, cingulate cortex and caudate putamen, 
although these changes did not reach significance. Neither of the 5 I-IT2 antagonists were 
able to change the haloperidol induced changes in any of the areas (Table 22, fig: 13, 
page 118-119).
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Fig 13. Effect of haloperidol, haloperidol+5HT% receptor antagonists, olanzapine and Y-931 on 
fra-2 mRNA expression levels in dorsolateral caudate putamen (DLCPu), three hours after APD 
treatment.
Data shown as mean optical density (ROD) ±SEM and mean percentage of vehicle control 
(control=100%, n=6-8 per group). Data analysed by one way ANOVA followed by LSD 
multiple range tests where appropriate.
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Effect of haloperidol, haloperidol+S-HTz antagonists, olanzapine and Y-931
on the GAD mRNA expression levels.
The effect of haloperidol, olanzapine and Y931 on GAD67 inRNA expression and effect 
of 5 HT2 antagonists to modulate haloperidol induced changes in different areas of basal 
ganglia are shown in table 23 and Fig. 14 and 15. In this experiment, GAD 67 mRNA 
levels were significantly lowered after treatment with Y931 and olanzapine but not with 
haloperidol in the globus pallidus as compared to vehicle controls. The expression level 
of GAD67 mRNA was significantly less after treatment with haloperidol than that witli 
Y931. Interestingly, although olanzapine also decreased GAD 67 mRNA expression in 
level in this region, the expression level of GAD mRNA after treatment with Y931 was 
considerably lower than that of olanzapine. The pretreatment with SB242084 (SB2), the 
selective SHTic receptor antagonist, but not SB200464 (SBl), reduced GAD 67 mRNA 
expression level in the lateral globus pallidus compared to controls. Treatment with 
olanzapine and Y931 also decreased GAD67 mRNA expression level in this region. In 
the caudate putamen, substantia nigra pars reticulata and in the lateral part of substantia 
nigra, no changes were observed in any of the treatment groups (Table 23, fig: 14 &15, 
page: 121-123).
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Fig 14. Effect of hal, hal+SBl, hal+SB2, olanz and Y-931 on GAD 67 mRNA expression level 
in globus pallidus (LGP), caudate putamen (Cpu) and substantia nigra pars reticulata (SNR),three 
hours after APD treatment. Data shown as mean optical density (ROD) ±SEM and mean 
percentage of vehicle control (control=100%, n=6-8 per group). Data was analysed by one way 
ANOVA followed by LSD multiple range tests where appropriate. *p<0.05 compared to respective 
vehicle. # = significantly lower than haloperidol p<0.05
122
1) Veh/Veh Lateral globus pallidus 2) Veh/haloperidoi
3) Veh/olanzapine
4) Veh/Y931
Fig. 15. In situ hybridisation autoradiographic localization of GAD 67 mRNA expression in rat 
brain at the level of globus pallidus (LOP) and caudate putamen (Cpu) (Level-2). Rats were 
treated with vehicle-1 (0. 5%HPMC), haloperidol -2  (1 mg/kg), olanzapine-3 (10 mg/kg) and 
Y931-4(10mg/kg).
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Effect of haloperidol, haloperidol+5-HT2 antagonists, olanzapine and Y-931
on the NOS mRNA expression levels.
The table 24, shows that there was no significant change in the expression level of nitric 
oxide synthase (NOS) mRNA in the subthalamic nucleus (STN) after three horns 
treatment with haloperidol, olanzapine or Y-931. Whilst the NOS mRNA expression 
level appeared lower than the vehicle control after treatment with Y931, this was not 
significant.
124
§o
o
o<N ooo
i
§
o
I
8
8
CO
N
O II
Î
I
00VO
8
I
I1
II
I'Ti
H"l
I
i
I
00
W(DI
I1
■II
I
ê
Effect of haloperidol, haloperidol+5-HT2 antagonists, olanzapine and Y-931
on the grp-75 mRNA expression levels.
After three horns treatment with haloperidol, olanzapine and Y-931, the expression level 
of glucose regulating protein (grp-75) mRNA was significantly higher in the subthalamic 
nucleus (STN) with all three drugs. The expression level of grp 75 mRNA, was largest 
following treatment with Y931, although it was not significantly greater than any of the 
other groups. Pretreatment with the serotonin antagonists did not seem to make much 
change in the pattern of mRNA expression level as compared haloperidol alone.
In substantia nigra pars compacta (SNCD), although there was no significant change in 
the expression level of grp-67 mRNA, there was a tendency of 5 HT2c receptor antagonist 
SB242084 to lower the effect of haloperidol. In this area the expression level of grp75 
mRNA was lowest after treatment with Y931 (Table 25, fig 16 &17, page: 127-129).
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Fig 16 Effect of hal, hal+SBl, hal+SB2, olanz and Y-931 on glucose regulating protein mRNA 
expression level in subthalamic nucleus (STN) and substantia nigra pars compacta (SNCD), 
three hours after APD treatment. . Data shown as mean optical density (ROD) ±SEM and mean 
percentage of vehicle control (control=100%, n= 6 to 8). Data analysed by one way ANOVA 
followed by LSD multiple range tests where appropriate. *p<0.05 compared to respective vehicle.
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1) Veh/Veh
' i . -
Subthalamic nucleus 2) Veh/haloperidol
X 'm\4 È S t
I
y- $  m m s :
^  i
3) Veh/olanzapine
E s # #
4) Veh/Y931
Fig 17. In situ hybridisation autoradiographic localization of grp-75 mRNA expression in rat 
brain at the level (Level-3) of subthalamic nucleus (STN). Rats were treated with vehicle-1 (0. 
5%HPMC), haloperidol -2 (1 mg/kg), olanzapine -3(10 mg/kg) and Y931-4 (10 mg/kg).
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Effect of haloperidol, haloperidol+5-HT2 antagonists, olanzapine 
and Y-931 on parvalbumin expression levels in different regions 
of rat brain.
After three hours treatment with haloperidol, olanzapine, and Y931, the expression level 
of parvalbumin mRNA levels were significantly higher than that of controls in the 
subthalamic nucleus (STN). The expression level of parvalbumin mRNA was very 
similar to that of haloperidol after treatment with Y931. Pretreatment with the 5 HT2b+2c 
receptor antagonist SB200646 (SBl) significantly attenuated haloperidol induced 
changes in parvalbumin mRNA expression in this region.
Parvalbumin mRNA expression levels were also higher (P<0.07) than that of controls in 
the lateral globus pallidus after treatment with Y931, but not significant. However none 
of the other drug-treatments affected parvalbumin expression level in this region.
There were no significant changes in the expression level of parvalbumin mRNA in any 
other regions examined, such as substantia nigi a pars reticulata or caudate putamen. 
(Table-26 and fig: 18 & 19, page: 131-133)
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Fig 18. Effect of haloperidol, haloperidol+5HT2 receptor antagonists, olanzapine and Y-931 on of 
Parvalbumin mRNA expression levels in subthalamic nucleus (STN) and in globus pallidus 
(LGP),three hours after APD treatment. Data shown as mean optical density (ROD) ±SEM and 
mean percentage of vehicle control (control=100%, n = 6 to 8 per group). Data analysed by one way 
ANOVA followed by LSD multiple range tests where appropriate. *p<0.05 Compared to respective 
vehicle; # = significantly lower than haloperidol and Y931.
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1) Veh/Veh
2) Veh/haloperidol
Subthalamic nucleus
^0n
l ^ v ' ' \ T S• r,-#. ■ rf»i*;.-,T.V -..-
3) Veh/olanzapine Y931
Fig. 19. In situ hybridisation autoradiographic localization of parvalbumin mRNA expression in 
rat brain at the level of subthalamic nucleus (Level-3). Rats were treated with vehicle 1 (0. 
5%HPMC), haloperidol -2 (1 mg/kg), olanzapine -3(10 mg/kg) and Y931-4 (10 mg/kg).
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4.2.3.Summary of in situ hybridisation experiments, three hours 
after antipsychotic drug treatment.
There were no drug-induced significant changes in fra-2 mRNA expression in any of the 
Brain regions examined in this experiment after treatment with haloperidol (Img/kg), 
olanzapine (lOmg/kg) and Y931 (10 mg/kg). Nevertheless all three drugs showed a 
tendency to increase fra-2  expression in the dorsolateral caudate putamen and tliis was 
highest after treatment with Y931. There was also a tendency for all three drugs to reduce 
fra-2 mRNA expression in the ventromedial caudate putamen, with olanzapine being most 
effective in this respect.
The result after situ hybridisation showed that GAD 67 mRNA were significantly 
lowered after treatment with Y931 and olanzapine in the globus pallidus. After treatment 
with Y931, the GAD67 mRMA was also significantly lower than that of haloperidol. 
Haloperidol alone did not change GAD-67 mRNA expression level in the globus pallidus 
or caudate putamen. However, pretreatment with SB2 (5HTzc antagonist, SB 242084) 
resulted in a significant decrease of GAD67 mRNA in the lateral globus pallidus in 
haloperidol treated animals.
The GAD67 mRNA level was not changed in other brain areas examined after treatment 
with all three drugs.
There was no significant change in the expression level of NOS mRNA level three hours 
after treatment with haloperidol, olanzapine or Y931. From this result, it could be 
concluded that nitric oxide synthase (NOS) is not a good marker gene for our purpose.
Three hours after treatment with haloperidol, olanzapine, and Y-931, the expression level 
of glucose regulating protein (grp-75) was significantly increased in the subthalamic 
nucleus with all three drugs as compared to controls. Treatment with Y931 produced 
highest expression of grp mRNA, although this was not significantly greater than with
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haloperidol or olanzapine. Pretreatinent with the serotonin (2B / 2C) antagonists did not 
influence the antipsychotic drug-induced changes in the mRNA expression patterns.
After treatment with the three antipsychotic drugs, the expression level of parvalbumin 
mRNA was significantly higher than that of controls in the subthalamic nucleus (STN). 
Pretreatment with the 5 -HT2b+2c antagonist (SB200646) did lower the effect of 
haloperidol significantly, resulting in an expression level very similar to that of 
olanzapine. However, pretreatment with the S-HTic selective receptor antagonist 
SB242084, did not significantly alter the effects of haloperidol.
In the lateral globus pallidus (LGP), the expression level of parvalbumin mRNA did not 
change with haloperidol or olanzapine treatment in comparison to controls. But after 
treatment with Y931, it approached significance compared to controls (P<0.07) and 
appeared to reduce compared to haloperidol alone (p<0.052).
Although there were no significant changes in the level of parvalbumin expression levels 
in the motor cortex areas after any of the antipsychotic drug treatments, pretreatment with 
the 5 HT2C serotonin receptor antagonist SB200646 appeared to reduce the effect of 
haloperidol in M lL l and M1L2 considerably.
The results of grp 75, GAD67 and parvalbumin might indicate that Y931 affects the 
pallido-subthalamic pathway of the basal ganglia. This effect of Y931 is similar to that of 
haloperidol indicating that it might have the inclination to cause EPS.
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4.3.Summary tables of results
Results after forty-five minutes: lEG mRNA expression in different areas of 
rat brain (1®* experiment).
Brain area Zif268 c-fbs
hal Y931 hal Y931
C gl \—>
Cg2 <-)■
Motor- 
corteK 1 
Layer-1
<—> <->
Motor cortex 1 
Layer-2
<-> <—>
Motor cortex-2 
Layer-1
<- <—>
Motor
Cortex-2
Layer-2
Sensory motor 
cortex-1 
Layer-1
m i NM r
Sensory motor 
cortex-1 
Layer-2
NM NM
r
R SA l NM NM <—> <—>
RSA2 NM NM 1*
Ventro-Medial-
Caudate-
Putamen
'I'*
<r~>
Dorso-Lateral-
Candate-
Putamen
AcbSh <—>
AcbC 'I'*
Table 27. Summary of changes in the gene mRNA expression levels produced by the 
acute treatment with haloperidol (hal) and Y931.
NM
hidicates significant increase in gene expression compared to vehicle control 
Indicates significant_decrease in gene expression compared to vehicle control 
Indicates not significantly different from vehicle control 
Indicates not measured
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Results after forty-five minutes: lEG m RNA expression (2"^  experiment).
Brain area Zif-268 c-fos
hal olanz Y931 hal olanz Y931
Cgl 4—X <—>■
Cg2 <—> « - >
Motor-
Cortex-1 Layer 1 4-» < -> 4 -4 -
Layer-2 <—> < - > 4 —^
Layer-3 < -> <—>
Layer-5 <r-> 4-* < - > < - > 4 - ^
Motor cortex-2 
Layer-1
<—> < - > 4 - ^
Layer-2 4 - ^
Layer-3 4,* < - > 4 - >
Layer-5 < - > 4,* 4—^ 4 - ^
Sensory motor 
cortex-1 
Layer-1
NM NM NM NM NM NM
Sensory motor 
cortex-1 
Layer-2
NM NM NM NM NM NM
RSAÏ NM NM NM NM NM NM
RSA2 NM NM M N M NM NM
Dorso-Medial-
Caudate-
Putamen
<->
Ventro-Lateral-
Caudate-
Putamen
<->■
AcbSh N M NM NM NM NM NM
AcbC NM NM NM NM N M NM
Table 28. Summary of changes in the lEG mRNA expression levels produced by the 
acute treatment with haloperidol (hal), olanzapine (olanz) and Y931 for the second 
experiment.
T* Indicates significant increase in gene expression compared to vehicle control
<r->
NM
Indicates significant_decrease in gene expression compared to vehicle control 
Indicates not significantly different from vehicle control 
Indicates not measured
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Chapter 5: Discussion
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5.1.General Discussion
Each antipsychotic drug has its own specific pharmacological profile ultimately 
determining its effect on different targets in the brain.
Several new antipsychotic drugs have full antipsychotic action and low motor side effect. 
Evidence suggests that the therapeutic action of most atypical antipsychotic drugs cannot 
be attributed to the action of any single receptor system. It is more likely to be due to the 
combined activity at some or many neurotransmitter receptors (Bymaster et al. 1997) that 
are involved in the action of the specific antipsychotic drug. Previous work showed that 
this multi-affinity profile is also the characteristic of Y931 (Morinioto et al. 2002),
The receptor binding profile of Y931 is similar to that of olanzapine, but with a liigher 
affinity to the dopamine D2 receptor. Y931 also has high affinity for several other receptors 
like olanzapine and clozapine, e.g., 5 HT2, 5HT?, a-adrenoreceptors, muscarinic receptors 
M l, M2, M3, M4, M5 and histamine HI receptors. It is believed that EPS is associated with 
potent D2 antagonist activity of antipsychotic drugs. This receptor site is also the potential 
site of antipsychotic action of all APDs.
The results from the present lEG studies showed that, in our first study, Y931 produced 
relatively less induction of zif 268 in the motor cortex than haloperidol. However, in our 
second study, we tried to use more intricate method of image analysis to monitor the 
signals in the individual layer of cortex, which failed to confinn this finding. Haloperidol 
and Y931 both induced zif268 mRNA expression in the accumbens core. After treatment 
with haloperidol or Y931, the zif-268 and c-fos lEG expression levels were very similar 
in dorso-lateral and ventro-lateral caudate putamen. Both c-fos and zif-268 mRNA 
expression levels were significantly enhanced after treatment with haloperidol and Y931. 
But after treatment with Y931, the expression level of c-fos mRNA was far greater in the 
dorsolateral caudate putamen, than after treatment with haloperidol. This may reflect 
Y93Ts higher affinity for D2 dopamine receptor. But in the ventro-lateral caudate- 
putamen, the c-fos expression level was increased by haloperidol but not by Y931.
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Thus, Y931 induces a similar pattern of change in lEG expression in the striatum to 
haloperidol This is consistent with evidence that D2 receptor antagonism is responsible 
for increases in the striatal lEG expression.
It would therefore be expected that Y931 would cause EPS. Thus our results of lEG 
expression suggest that the activity of Y931 could not suppress EPS through it’s 
mechanisms inside the striatmn.
However, it had been suggested that Y931 produces no or very little EPS (Morimoto et 
a l, 2002).
In our study, pretreatment with the 5 HT2 antagonists (SBl and SB2) employed in this 
study did not affected haloperidol s ability to induce striatal ÏEG expression. This would 
imply, any ability o f these serotonergic drugs to modify EPS could be somewhere 
downstream of the striatum.
Part of the reason for this effect could be Y931’s very high affinity towards SHTic 
receptors. It is believed that 5 HT2C receptor antagonists may inhibit centrally mediated 
hypolocomotor response (Kennett 1993; Di Matteo et a l, 1999). It is also believed that 
5 HT2C receptor antagonists may attenuate haloperidol-induced catalepsy (Kemiett et al, 
1997; Meltzer et a l, 1996; O’Neill et a l, 1999; Reavill et a l, 1999; Poyurovsky and 
Weizman, 1997). The serotoninergic system has been implicated in the regulation of 
immediate early genes in the striatum. Activation of serotonin 5HT2c receptors has been 
demonstrated to cause a localised expression of immediate early gene c-fos and this 
induction could be selectively blocked with a 5HT2c antagonist (Leslie et a l, 1993).
Neither of the 5HT2c antagonists in our experiments, showed significant ability to reduce 
the haloperidol induced striatal lEG expression, hence any ability of these drugs to 
modify EPS must be downstream of the striatum.
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According to the double blind PET study by Kapur and colleagues (2000a, 2001), it was 
found that the clinical response of antipsychotic drugs (APD) was manifested at 65-70% 
Di receptor occupancy and patients with a D2 receptor occupancy >78% with 
antipsychotic treatment, showed signs of EPS. For example, risperidone becomes 
effective at a dose of 2mg/day, which is associated with 65% D2 receptor occupancy with 
very little EPS, while risperidone 6 mg/day leads to a D2 receptor occupancy of >80% 
and is associated with EPS. With olanzapine, similar efficacy appears to begin at 10 mg / 
day, a dose that leads to 70% D2 receptor occupancy; while 30-40 mg / day of olanzapine 
(effective medical dose) results in D2 receptor occupancy >80% and EPS. The threshold 
of D2 receptor occupancy lies in the range of 65%~70% (Kapur et al. 1999; Kapur et. al. 
2000a, 2000b; Farde.et.al. 1992). Quetiapine, on the other hand, produced modestly high 
(58-64%) D2 receptor occupancy, and only transiently, after 2-3 hours of a single dose, 
and never exceeded 80% and never produces EPS (Kapur et al. 2000b). Thus, the discrete 
difference between physiologically active dose and therapeutic dose makes a great 
difference in the expression of EPS, as aiming for the maximum tolerated levels of 
antipsychotic drugs is the aim of clinical practice. Whilst it appears that D2 receptor 
occupancy is a factor in the development of EPS, other receptors may also be important.
The high affinity for 5 HT2 receptors has been receiving much focus in recent years in 
relation to atypical antipsychotic drugs. It had been suggested that the balanced 
antagonism between 5HT2 receptors and D2 receptors might contribute to a lower EPS 
incidence (Meltzer et al., 1989,1991; Barnes and Sharp 1999; Bymaster et al., 1996; 
Kapur et al., 1999; Pilowsky et al 1992; Stockmeier et al 1993). 5-HT neurons innervate 
both the dopamine cell bodies in the substantia nigra pars compacta and the ventral 
tegmental area, and their projection terminal fields in the striatum, nucleus accumbens 
and frontal cortex. Therefore, 5-HT mechanisms are well placed to modulate 
dopaminergic processes (Wolf et al., 1997). Y931 has high affinity for 5 HT2C receptors. 
It has been suggested that 5HT2c receptor antagonists attenuate haloperidol induced 
catalepsy (Reavill et al., 1999; Meltzer et al., 1996; Wood et a l, 2001). But this ability of 
5HT2C receptor antagonist was not evident in our catalepsy experiments. Pretreatment 
with the two most robust receptor antagonists (SB200646, a mixed 5-HT2c+2b receptor
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antagonist and SB242084, a selective 5-HTzc receptor antagonist) did not reverse the 
haloperidol induced catalepsy significantly although there appeared to be a modest effect 
of SB 200646. A similar result was found by other researchers with other potent S-HTsc 
antagonists (Bonhaus et al., 1997; Di Matteo et al., 1999; Kennett et a l, 1994). Although 
another group (Kalkman et a l, 1998) reported that the SHTib/zc receptor antagonist 
SB200646 could not attenuate catalepsy induced by loxapine, a D2 receptor antagonist. 
And again, another group did find that a 5HT2b/2c antagonist SB200646 could attenuate 
haloperidol-induced catalepsy significantly, while the 5 HT2B/2C antagonist SB215505 did 
not do so (Reavill et a l , 1999). Although the relative D2 : 5HT2 receptor binding 
affinities, as well as behavioral effects, have been implicated as important to the atypical 
mechanism of action, the actual degree of receptor occupancy of multiple 
neurotransmitters achieved during antipsychotic drug treatment may instead be crucial to 
determining the functional profile of an antipsychotic drug. Also, doses of haloperidol 
producing 25% striatal and limbic D2 receptor occupancy will not produce significant 
serotonergic, adrenergic, histaminergic or muscarinic receptor occupancy (Kinon and 
Lieberman, 1996).
In the behavioural study, our initial result showed that with 1 mg/kg of haloperidol treatment, 
at 60 mins post APD, there was no emergence of catalepsy, but these animals were 
cataleptic at a later time. However, the fact that not all animals tieated with haloperidol 
developed catalepsy led us to further investigate the effects of SB 200646 against a dose of 
haloperidol that produced reliable catalepsy. In our second experiment for haloperidol 
induced catalepsy, 2mg/kg haloperidol effectively produced catalepsy in all animals in the 
group at 90 mins onwards. This confirmed the fact acknowledged by other researchers 
(Kapur et a l ,  2000a, 2000b) that catalepsy (a marker for EPS) induced by haloperidol 
and other typical high potential antipsychotic drugs, is probably dose dependent.
The results of our first behavioural experiments were different after treatment with 
olanzapine and Y931 from what was expected. After 60 mins of APD treatment little 
catalepsy was induced by olanzapine and Y931 at this time point, although the Y931 
treated rats appeared somewhat sedated. This may reflect olanzapine’s very low affinity
143
for a-2 receptors and HI receptors as compared with Y931 and also reflect its less 
sedative actions. After 120 mins the behaviour of animals treated with Y931 changed. 
The animals behaved differently with different tests at this time point. In the block test, 
more of the Y931 treated animals appeared cataleptic (sedated), althougli in the grid test 
this was not apparent. One possible explanation o f these differences is that the animals 
were experiencing sedation rather than catalepsy and that this was more apparent in one 
test than the other. Sedated animals would be drowsy and may show a greater propensity 
to stay on the block. The high affinity of Y931 for HI receptors would be consistent with 
a sedative effect.
In our second set of behavioural experiments using the bar test for assessment of 
catalepsy treatment with Y931, the animals appeared sedated (cataleptic?) even after 180 
mins. And 90 mins onwards, after treatment with olanzapine 50% of the animals also 
appeared cataleptic (sedated?).
Thus, the ability of these tests to discriminate between cataleptic and sedative effects was 
not totally clear. In future experiments it might be possible to determine if the catalepsy 
measures were being confounded by sedation by assessing the anim als response to a 
sensory stimuli. Thus if an animal was experiencing sedation it would not be expected to 
show a startle response to a loud noise, whereas a cataleptic animal would be expected to 
respond to that.
In summary, the results of the catalepsy tests concluded that the addition of a 5HT2c/2b 
receptor antagonist may show a weak ability to attenuate haloperidol induced catalepsy. 
The selective 5 HT2c antagonist (SB2, SB242084) on the other hand, was ineffective. 
Previous studies regarding the effects of mixed 5 HT2a/2c (SB 200646A) and 5 HT2c/2b 
(SB200646) receptor antagonists on dopamine D2 receptor-mediated catalepsy are also 
inconsistent. SB206553 (a 5 HT2c/2b receptor antagonist with higher affinity for 
5 HT2cfeceptors than SB200646) also showed variable response. The results varied 
between attenuation (Reavill et al., 1999), inhibition, (Kennett et al., 1994; 1996; Lucas 
et al., 1997), no effect (Wadenberg, 1992) or potentiation (Elliott et a l , 1990). Whilst
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inconclusive, because of the possible confounding effects of sedation of Y931, it is 
possible that the higher receptor affinity of Y931 for SHTzc/zn receptors may contribute to 
its lack of catalepsy.
It had been suggested that Di receptor stimulation is necessary for the expression of 
postsynaptic D2 receptor mediated functional responses and normal motor behaviour 
(Gershanik et al., 1983). But this relationship is not mutual since D2 receptor activation is 
not necessary for Dpnediated motor responses (White et a l, 1988). It had also been 
suggested that Dz- antagonist-induced catalepsy is mainly mediated via activation of strio- 
pallidal GAB A pathways whereas Di receptor antagonist induced catalepsy is mainly 
mediated via increased activity in the nigrothalamic G ABA pathways (Ogren S O and Fuxe 
K, 1988). Therefore alterations of Di receptor activity may play important roles in the 
pathophysiology of disorders of DA neurotransmission such as Parkinson’s disease and 
drug-induced Parkinsonism in schizophrenia. Thus the fact that the different doses of 
haloperidol did not correlate with the degree of lEG expression in the striatum and 
production of catalepsy, may have some relation to this Di/ Dz interaction and this 
relationship needs further investigation. Although there was a reduction in the GAD67 
expression level after treatment with Y931 and also after pretreatment of haloperidol with 
SB2 (SB242084), SB242084 did not reduce haloperidol-induced catalepsy. Like clozapine 
Y931 is also a mixed Di/ Dz antagonist. But, while clozapine is a weak Di/ Dz antagonist 
causing partial blockade of both receptor types, Y931 is a much stronger D /  Dz antagonist 
similar to that of haloperidol Thus we could not conclude that reduction of pallidal GAD67 
expression with Y931 would play a role in attenuating EPS.
Studies related to Parkinson’s disease suggests that the neurochemical phenotype of the 
parkinsonian basal ganglia includes an increase in the neuropeptide enkephalin mRNA 
expression in the stiiatum and a decrease in the striatal substance P mRNA expression with 
increased cytochrome oxidase 1 (CO 1) mRNA in the STN. This suggests an increased STN 
neural activity. There is also increased glutamate decarboxylase-67 (GAD 67) mRNA 
expression in the globus pallidus (Salin et al., 1997). Not very much is known about any
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other neuropeptide in relation to basal ganglia activity after antipsychotic drug treatment and 
occui rence of EPS.
In our experiment for marker genes, neither haloperidol nor Y931 altered the expression 
level of GAD 67, grp-75 or NOS mRNA in the discrete regions of basal ganglia, e.g., 
subthalamic nucleus and / or substantia nigra, after 45 mins of antipsychotic drug 
treatment. Despite the change in c-fos and zif 268 mRNA at this time point, there was no 
haloperidol-induced catalepsy at this time point either. Hence these results are consistent 
with the idea that these genes are affected more slowly than lEGs and these genes were 
not good markers of regional activity at the time point studied here.
The effect of haloperidol, olanzapine and Y931 on the marker genes were examined 
again, three hours after the drug treatment, together with pretreatment with the serotonin 
5HTic antagonists 15 mins before haloperidol treatment. The results showed specific 
alterations of mRNA expression levels with some of the marker genes.
GAD67 mRNA was expressed, at significantly lower levels than the controls, in the 
lateral globus pallidus (LGP) after treatment with olanzapine and Y931, but not with 
haloperidol. These results are very similar to that of Dz receptor deficient mice, observed 
by Murer et al. (2000) and Sakai et a l ,  (2001). In haloperidol treated animals, the level of 
GAD67 mRNA expression (three hours after treatment) was signiEcantly lowered in the 
animal group that was pretreated with serotonin antagonist 5HTzc receptor (SB 2420084), 
bringing it to the same level as that with Y931 and olanzapine. This could be the 
evidence that reduced pallidal GAD67 expression acts to attenuate EPS initiated by Dz 
dopamine receptor antagonism in the striatum. The decreased pallidal neuronal activity, 
which presumably reflects decreased GAD67 expression, may result in abnormal increased 
afferent signal from STN to SNR.
From the study of basal ganglia models and the study of Parkinson’s disease many 
authors deduced that the reduced pallidal GAD67 expression acts to attenuate the 
tendency towards EPS initiated by Dz dopamine receptor antagonism in the striatum as
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decreased GABAergic activity in the pallido-subthalamic pathway is the major factor 
associated with EPS (Delfs et a l, 1995; Vila et a l , 1997; Schoeder and Schneider, 2001). 
In our study, GAD67 mRNA expression was not different from control with haloperidol 
alone either 45minutes or three hours after treatment. Pretreatment with the 5-HTzc 
antagonist SB242084 (SB-2) significantly lowered the haloperidol induced GAD67 
mRNA expression level This result is very similar to GAD67 mRNA expression level 
after treatment Y931 and olanzapine. The GAD67 mRNA expression after treatment with 
Y931 (three hours after treatment) was also significantly lower than that of haloperidol 
alone. This may suggest that the change by Y931 could be due to its high affinity for 
5 HT2C receptor. Thus, this reduced pallidal GAD67 expression could be the mechanism 
that may make Y931 less liable towards EPS initiated by Dz dopamine receptor 
antagonism in the striatum. And yet there was no clear relationship between the drugs or 
drug combinations used in this study to reduce catalepsy. Further study is needed to clear 
this anomaly.
Nitric acid synthase (NOS) mRNA expression did not change with our drug treatment 
even three hours after drug treatment in any areas of rat brain. But grp75 mRNA 
expression was increased in subthalamic nucleus by haloperidol alone and also, in 
combination with either of the serotonin antagonists, and also with Y931 and olanzapine. 
Dopamine or dopamine agonists increase glucose utilisation and discharge frequency of 
STN neurons. Our findings are in line with the findings that in drug induced 
parkinsonism or EPS, STN becomes hyperactive as a result of disinhibition via GPe in 
the indirect pathway (Henderson et a l ,  1999; Vila et a l ,  1997, 2000; Robledo and Féger, 
1990). But there was no correlation between grp75 expression in STN and the degree of 
catalepsy detected in the animals. Other investigators also reported decreased, increased 
or even mixed effects of dopamine on the frequency of discharge of neurons of the STN 
(Campbell et a l , 1985). Such different effects could also be of a different action of 
dopamine on Di and Dz receptor subtypes- which are known to be in the Striatum, SNr 
(Dawson et a l, 1987) and STN (Brown et a l, 1979; Marters et a l , 1985). Y931 has high 
affinity for the Di receptors. As previously mentioned, it had been suggested that Dz- 
receptor antagonist induced catalepsy is mediated via increased activity of striato-pallidal
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GAB A pathways whereas D1-receptor antagonist induced catalepsy is mainly mediated 
via increased activity in the nigrothalamic inhibitory (GABA) pathways. Thus different 
neuronal networks containing different receptor populations and transmitters, may be 
involved in the catalepsy caused by D% and D% receptor antagonists (Ogren S O and Fuxe 
K, 1988; Morelli and Chiara, 1985). In our study, whilst all three antipsychotic drugs 
induced increased grp75 mRNA expression in the STN, only haloperidol produced clear 
catalepsy in all animals in this treatment group, which may reflect this aspect of striatum, 
SNR and STN nucleus.
GABAergic neurons can be defined by the presence of one of three essentially non­
overlapping calcium binding proteins (CBPs): parvalbumin, calretinin and calbindin 
(Reynolds e t a t, 2001; Marshall et al. 1998). Reports from post mortem tissue analysis 
of schizophrenic patients revealed that parvalbumin (PV), but not calretinin containing 
cells were significantly diminished in schizophrenia (Nitsch et al., 1989). Thus 
parvalbumin appears to be a very important marker for GABAergic neuronal subtypes.
Our experiment showed that the expression level of parvalbumin mRNA increases 
significantly relative to the control, after treatment with all three dixigs: haloperidol, 
olanzapine and Y931 in the subthalamic nucleus (STN). Pretreatment with the selective 
5HT2C receptor antagonist SB 242084 with haloperidol lowered the effect of haloperidol 
slightly. It is interesting to note that the result after pretreatment with SB200646 (5HT2c+2b) 
did lower the effect of haloperidol considerably, which was more like that of olanzapine, 
where as the result of pretreatment with SB242084 was more like that of Y931.
Once again, as with gi‘p75 mRNA expression, there did not appear to be a correlation 
between the extent of drug-induced parvalbumin expression and the degree of catalepsy 
detected.
There was no change in the mRNA expression level of the nitric oxide synthase (NOS) in 
the cerebral cortex, STN, striatum or nucleus accumbens with any of the drugs at any 
time points (45 mins or 3 hours after acute treatment). Again, this contrasts with the
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reports that NOS mRNA expression is a sensitive indicator of the activity of STN (Nisbet 
et ai., 1994; Bel et al., 2000; Shinde et al., 2000).
The mRNA encoding SHT^ c receptors is highly expressed in the subthalamic nucleus 
(Eberle-Wang et. a l, 1997). The subthalamic nucleus receives a cortical innervation in 
the rat. This direct cortico-subthalamic projection is excitatoiy and glutamatergic. There 
is also dopaminergic innervation of the frontal cortex of rat brain. The neurons in the 
frontal cortex express D% and D2 receptors. Since the activation of these dopaminergic 
receptors decreases the glutamatergic transmission, it could be hypothesised that the Di 
antagonism in these area leads to increased activity of the excitatory cortical neurons 
projecting to the subthalamic nucleus (Hassani e ta l ,  1996).
The STN projects to, and influences the activity of major output nuclei of basal ganglia: 
globus pailidus (GP) and substantia nigra reticulata (SNr). The main neurotransmitter 
used by the STN is glutamate. As described above, it is rich in PV positive neurons, 
which is usually a GABA marker. The PV positive sectors of STN appear related to the 
GP and cerebral cortex. Subthalamic lesions alleviate parkinsonian symptoms in animals 
showing the importance of the STN in the control of motor behaviour (Aziz et. a l , 1991). 
The presence of both mRNA and binding sites for 5HT2c receptors in the STN suggests 
that these receptors are expressed by intrinsic subthalamic neurons. The major target 
areas of these neurons are the pallidum and SNR, the main output structures of the basal 
ganglia.
It had been proposed that in the STN, 5HT2 receptor stimulation is associated with an 
increased firing rate of the STN neurons. Hence SHTic receptor antagonism may act to 
reduce STN firing that has been elevated by striatal D2 receptor antagonism. From our 
results it is evident that the drug SB200646 (a selective 5HT2c/2b antagonist) and the 
drug SB242084 (a selective 5HT2c antagonist) were not as effective as expected in 
restoring altered gene expression following haloperidol treatment. SB 200646 is a 
selective 5 -HT2C/2B receptor antagonist with pki value of 6.9 for serotonin-2c receptors 
(Forbes et a l , 1995) and with pki value of 7.5 for serotonin 2b receptors. SB200646 has
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50-fold selectivity for 5-HT2c and 5-HT2b over 5-HT2A receptors (Kennett et al., 1994). 
Where as, SB 242084 is a selective 5 -HT2C receptor antagonist with pki value 9.0 for 
serotonin 2c receptors. It has 100 and 158-fold selectivity over the 5 -HT2B and 5-HT2a 
receptor subtypes respectively. Thus SB242084 can be used to evaluate the effect of 
selective blockade of 5-HT2C receptors. (Di Matteo et al., 1999). The results indicate that 
5 HT2C+2B antagonist had more influence on the effect of D2 antagonism on some of the 
regional marker genes of the basal ganglia.
The antagonism of D2 dopamine receptors, or dopaminergic depletion in the striatum, is 
predicted to cause increased activity of the GABA-ergic striatal neurons projecting to the 
globus pailidus. This should cause increased GABA release. But if  the GABA-ergic 
pallidosubthalamic neurons were then inhibited, there would then be an increase in the 
subthalamic neurons discharge rate. However, a subthalamo-pallidal projection 
influences the pallidal neurons, which express GAD67 mRNA. Thus the activity of the 
pallidal neurons may also be regulated by the subthalamic nucleus (Hassani et. al., 1996). 
So, the activity of the pallidal neurons may also be regulated by the subthalamic nucleus, 
which is assigned as the area of convergence of inhibitory and excitatory inputs on the 
pallidum (Hassani, 1996; Parent, 1995), not just a relay station for the indirect pathway. 
Thus it could be that alteration of both serotonergic and dopaminergic neurotransmission 
may be needed to reduce the motor symptoms in the EPS. Some researchers (Eberle- 
Wang etal., 1996) showed that there could be dopaminergic / serotonergic interactions in 
the STN. Thus EPS produced by some antipsychotic drugs could have resulted from 
direct or indirect alterations in the activity of subthalamic neurons respectively. It is 
believed that the hyperactivity of these glutamatergic STN projection neurons to the 
globus pailidus (GPi) may be a cause of hypoactive movement disorder and 
extrapyramidal side effects of the neuroleptic drugs. Thus the results for grp-75 and 
parvalbumin expression levels in the STN suggest that, our hypothesis that Y931 may 
suppress EPS by its ability to influence indirect pathway via its higher affinity for 5HT2c 
receptor at a site out side striatum, is unlikely to be correct.
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In addition to the GABAergic inhibitory projections from the striatum, GPe receives a 
dense glutamatergic excitatory input from the STN. This double innervation suggests that 
the activity of GPe neurons results in the counter balancing of the activity of these two 
convergent pathways; the inhibitory pathway arising from the striatum and the excitatory 
input from the STN, producing normal or increased activity of GPe neurons (Levy et al., 
1997). The STN may not be the only excitatory input responsible for the activation of 
GPe neurons. Other excitatory inputs could maintain or increase the activity o f the GPe in 
the normal state or Parkinsonian state, e.g., the parafascicular nucleus of the thalamus (Pf 
nucleus), which sends projection to the GPe. The STN also receives projections from 
glutamate-excitatory afferent projections from the cerebral cortex, the glutamate- 
excitatory projections from the parafascicular nucleus of the thalamus (Pf nucleus) 
(Parent et a l , 1995; Mouroux et a l, 1993). The cerebral cortex and Pf nucleus are 
glutamatergic and can cause hyperactivity seen in the STN. However, the precise 
influence, or any crucial role of each of these afferent systems to reduce the drug induced 
Parkinsonism after treatment with Y931, need to be determined by further study.
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5.2.Conclusion
Thus from the above discussion, the following conclusions can be made:
According to our first hypothesis, Y931 acts within the striatum to suppress the activation 
of indirect pathway, despite blocking striatal D2 dopamine receptors. But, haloperidol, 
olanzapine and Y931 all tend to increase striato-pallidal activity, as assessed from the 
lEG expression in the striatum. Furthennore, they all also tend to increase STN activity, 
as assessed by gip75 and parvalbumin mRNA expression level although these changes in 
gene expression did not correlate with drug induced catalepsy. Thus the reduced EPS 
liability o f Y931 is unlikely to be due to actions in the striatum.
In our second hypothesis, we suggested that Y931 acts outside the striatum to suppress 
the activation of the indirect pathway and it could be via its relatively high affinity for the 
5 HT2C or muscarinic M3 receptors. Our results do not provide clear support for the 
hypothesis that either 5HT2b and / or 5HT2c receptor antagonism suppresses the 
appearance of EPS. Our results also are not clear about the activity of 5HT2c receptors in 
controlling antipsychotic drug induced catalepsy. We did not manage to explore the 
possibility of M3 receptor as an appropriate compound was not available at the time. 
Thus the reduced EPS liability of Y931, if any, may lie with some other feature of the 
compound.
Our third hypothesis speculates that Y931 may facilitate and elevate the activity of the 
direct pathway thus balancing the indirect pathway and control EPS. But our results do 
not show any direct evidence to this effect.
Y931 increase striato-pallidal activity. It very strongly increases the activity of 
subthalamic nucleus, thus increasing activity of the indirect pathway from the striatum to 
the substantia nigra.
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Thus the action of Y931 to suppress EPS due to D2 receptor antagonism in the striatum is 
likely to be down stream of the substantia nigra. The anatomical and pharmacological 
locus of Y931 in suppressing EPS, if  any, remains to be identified.
How atypical antipsychotics achieve their advantages over conventional antipsychotic 
agents remains uncertain. Each o f these agents has a somewhat distinct profile in terms of 
specific serotonin and dopamine sub-receptor affinity, and affinity for other 
neurotransmitters receptors. There is no consensus as to what combination or ratio of 
receptor activities is essential for the clinical advantage shown. The explanation for the 
reported low profile of Y931 in experimental models therefore remains to be determined.
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Appendix:
Statistics where ANOVA has been significant.
Table no. 8: zif 268
Region Degree o f  reference 
(df)
F P
M1L2 2,21 3.924 0.036
M2L1 2,21 4.386 0.026
Cgl 2,21 6.242 0.007
Cg2 2,21 4.569 0.023
DLCPu 2,21 19.648 0.000
VMCPu 2,21 17.737 0.000
AcbC 2,21 8.370 0.002
Table no. 9: c-fos
Region Degree o f reference 
(df)
F P
Cgl 2,19 4.300 0.29
M2L2 2,19 3.950 0.037
VMCPu 2.19 3.826 0.040
DLCPu 2,19 13.876 0.000
RSAL-2 2,20 4.893 0.019
S lL l 2.19 5.368 0.014
S1L2 2,17 10.677 0.001
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Table no. 10; zif 268
Region Degree o f  reference 
(df)
F P
M lL l 3.20 5.990 0.004
M1L2 3.20 5.608 0.006
M1L3 3.20 5.598 0.006
M2L1 3,20 5.058 0.009
M2L2 3,20 9.254 0.000
M2L3 3,20 4.564 0.014
Table no. 11: zif 268
Region Degree o f  reference 
(df)
F P
M lL l 3,17 3.687 0.33
M1L2 3,17 4.157 0.22
M1L3 3,17 4.342 0,019
M1L5 3,17 4.822 0.013
M2L1 3,17 3.774 0.030
M2L3 3,17 4.822 0.013
M2L5 3,17 3.421 0.041
M IW 3,17 5.110 0.011
M2W 3,17 3.121 0.053
Table no. 12: c-fos
Region Degree o f  reference 
(df)
F P
DLCPu 3.14 7.574 0.003
VMCPu 3.14 4.575 0.020
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Table no. 23; GAD
Region Degree o f  reference 
(df)
F P
LGP 5.34 3.203 0.018
Table no. 25: grp
Region Degree o f  reference
(df)
F P
STh 5,33 3.191 0.019
Table no. 26: Parvalbumin
Region Degree o f  reference
(df)
F P
STh 5,30 6.725 0.000
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